
<!DOCTYPE html>
<!--[if lt IE 8]>      <html class="no-js nav theme-tan lt-ie10 lt-ie9 lt-ie8  " lang="en-us"> <![endif]-->
<!--[if IE 8]>         <html class="no-js nav theme-tan lt-ie10 lt-ie9  " lang="en-us"> <![endif]-->
<!--[if IE 9]>         <html class="no-js nav theme-tan lt-ie10  " lang="en-us"> <![endif]-->
<!--[if !IE]><!-->     <html class="no-js nav theme-tan  " lang="en-us" > <!--<![endif]-->	
    <head>
        <meta charset="utf-8" />
                <title>CDC - NIOSH Publications and Products - Toluene Diisocyanate (TDI) and Toluenediamine (TDA) (90-101)</title>
        		
                <meta name="keywords" content="Toluene Diisocyanate (TDI) and Toluenediamine (TDA), 90-101" />		<meta name="viewport" content="width=device-width, initial-scale=1" />
		        <link rel="apple-touch-icon-precomposed" sizes="144x144" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-144x144.png" />
        <link rel="apple-touch-icon-precomposed" sizes="114x114" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-114x114.png" />
        <link rel="apple-touch-icon-precomposed" sizes="72x72" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-72x72.png" />
        <link rel="apple-touch-icon-precomposed" href="../../../TemplatePackage/3.0/images/cdc-touch-icon-57x57.png" />
        <link rel="shortcut icon" href="../../../TemplatePackage/3.0/images/favicon.ico" />	
		
		<meta name="robots" content="index,follow" />
		<meta property="cdc:template_version" content="3.0" />
		<meta property="cdc:content-id" content="361447"/>
		<meta property="cdc:revision-id" content="6"/>
				<link rel="canonical" href="https://www.cdc.gov/niosh/docs/90-101/default.html"/>
				<!-- Internal Release Version # 3.6.3 -->
                			<link rel="stylesheet" href="../../../TemplatePackage/3.0/css/lib/bootstrap24.css" />
	<link rel="stylesheet" href="../../../TemplatePackage/3.0/css/app.css@3.2.1.7.css" />
	<!--[if gt IE 9]><!--><!--<![endif]-->
	<!--[if IE 7]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/lib/font-awesome-ie7.css" />
	<![endif]-->
	<!--[if lt IE 9]>
		<link rel="stylesheet" href="/TemplatePackage/3.0/css/ie.css" />
	<![endif]-->
	<link rel="stylesheet" media="print" href="../../../TemplatePackage/3.0/css/print.css@3.2.1.7.css" />
	<script src="../../../TemplatePackage/3.0/js/libs/modernizr-latest.js"></script>
	<script>
		if(!Date.now){Date.now=function now(){return new Date().getTime()}}
		var page_timing = page_timing || {};
		page_timing.page_start = Date.now();
		function $$(e){if(window.$){e()}else{setTimeout(function(){$$(e)},50)}}
		// (function(){function e(e,t){var n=e.length;while(n--){if(e[n].indexOf(t)>-1){return e[n]}}return false}var t=e(document.getElementsByTagName("html")[0].className.split(" "),"theme-");if(t){var n=document.createElement("link");n.rel="stylesheet";n.type="text/css";n.media="screen";n.href="/TemplatePackage/3.0/css/themes/"+t+".css";document.getElementsByTagName("head")[0].appendChild(n)}})();

		var settings = {}, addthis = null;
	</script>

	<meta name="application-name" content="CDC.gov"/>
	<meta property="cdc:template_version" content="3.2.1.7" />
	<meta name="msapplication-TileColor" content="#0061aa" />
	<meta name="msapplication-square70x70logo" content="/TemplatePackage/3.0/images/Win8_tile_70x70.png" />
	<meta name="msapplication-square150x150logo" content="/TemplatePackage/3.0/images/Win8_tile_150x150.png" />
	<meta name="msapplication-wide310x150logo" content="/TemplatePackage/3.0/images/Win8_tile_310x150.png" />
	<meta name="msapplication-square310x310logo" content="/TemplatePackage/3.0/images/Win8_tile_310x310.png" />
	<meta name="viewport" content="width=device-width,initial-scale=1,shrink-to-fit=no">		        


	<link rel="stylesheet" type="text/css" href="../../~inc~/local.css"/>
  
 <style type="text/css" media="all"> @import url("../../../TemplatePackage/css/B/theme-tan.css"); </style>

        <style type="text/css"> p.publink a {   font-weight:bold;  }  li.mySelection {   font-weight:bold;  }  table#activities, table#activities tr, table#activities td, table#activities th {  border:1px solid #cfcfcf;  padding:5px;  text-align:left;  vertical-align:top;  } </style> <script type="text/javascript">(function(H){H.id=H.id.replace('no-','')})(document.documentElement)</script>        
	<link rel="stylesheet" type="text/css" href="https://www.cdc.gov/migration/iteration5/niosh/local/b/css/local.css"/>
  		    </head>
    <body>
				



				<div id="skipmenu">
	<a href="index.html#searchTarget" class="skippy">Skip directly to search</a>
	<a href="index.html#azTab" class="skippy">Skip directly to A to Z list</a>
	<a href="index.html#nav-container" class="skippy">Skip directly to navigation</a>
	<a href="index.html#share-bar" class="skippy">Skip directly to page options</a>
	<a href="index.html#contentArea" class="skippy">Skip directly to site content</a>
</div>		    	<div id="wrapper">
    		
<!-- references to this removed intentionally -->
    		<header id="header">
    			<div class="container">
                    <div class="row">
                    	<div id="logo" class="span14">
                    		<!--iPad touch response and 508 voice reader issue currently under investigation -->
<a href="../../../index.html" title="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People">
	<img src="../../../TemplatePackage/3.0/images/masthead_subpage.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="hidden-one" />
	<img src="../../../TemplatePackage/3.0/images/masthead_1-col.svg" alt="Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People" class="visible-one" />
</a>

<!-- IOS9 iPad bug work around - make sure screen readers have a readable version of the logo to read
<a class="tp-sr-only" href="https://www.cdc.gov">Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People</a>
 -->
                    	</div>
                    	<!-- search -->
                    	<div id="searchArea" class="span10 hidden-one hidden-two">							
							
<div class="hidden"><a href="index.html#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper local">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="NIOSH">Search NIOSH</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>							<div class="a2z-button pull-right hidden-one hidden-two"><a href="index.html#" id="azTab">CDC A-Z Index <span class="icon-angle-down"></span></a></div>
                    	</div>
                    </div>
                    	<div class="hidden-three hidden-four" id="mobile-menu">
		<ul>
			<li id="vp1-menu-button" class="border-bottom-white"><a href="index.html#" id="menu-nav"><span class="sprite-16-menu"></span>MENU</a></li>
			<li id="vp1-a2z-button" class="border-bottom-white"><a href="index.html#" id="menu-az">CDC A-Z</a></li>
			<li id="vp1-search-button" class="border-bottom-white"><a href="index.html#" id="menu-search"><span class="sprite-16-search-white"></span>SEARCH</a></li>
		</ul>
	</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.menu_load = Date.now(); }</script>
                    <div class="a2z-bar hide">
                    	<div>
	<ul>
		<li><a href="../../../az/a.html">A</a></li>
		<li><a href="../../../az/b.html">B</a></li>
		<li><a href="../../../az/c.html">C</a></li>
		<li><a href="../../../az/d.html">D</a></li>
		<li><a href="../../../az/e.html">E</a></li>
		<li><a href="../../../az/f.html">F</a></li>
		<li><a href="../../../az/g.html">G</a></li>
		<li><a href="../../../az/h.html">H</a></li>
		<li><a href="../../../az/i.html">I</a></li>
		<li><a href="../../../az/j.html">J</a></li>
		<li><a href="../../../az/k.html">K</a></li>
		<li><a href="../../../az/l.html">L</a></li>
		<li><a href="../../../az/m.html">M</a></li>
		<li><a href="../../../az/n.html">N</a></li>
		<li><a href="../../../az/o.html">O</a></li>
		<li><a href="../../../az/p.html">P</a></li>
		<li><a href="../../../az/q.html">Q</a></li>
		<li><a href="../../../az/r.html">R</a></li>
		<li><a href="../../../az/s.html">S</a></li>
		<li><a href="../../../az/t.html">T</a></li>
		<li><a href="../../../az/u.html">U</a></li>
		<li><a href="../../../az/v.html">V</a></li>
		<li><a href="../../../az/w.html">W</a></li>
		<li><a href="../../../az/x.html">X</a></li>
		<li><a href="../../../az/y.html">Y</a></li>
		<li><a href="../../../az/z.html">Z</a></li>
		<li><a href="../../../az/0.html">#</a></li>
	</ul>
</div>
<script>if (typeof page_timing !== 'undefined') { page_timing.a2z_load = Date.now(); }</script>                    </div>
                    <div id="searchArea-two-column" class="span24 searchbar hide hidden-three hidden-four">
						  
<div class="hidden"><a href="index.html#" name="searchTarget">Start of Search Controls</a></div>
<form class="searchForm" method="get" action="https://search.cdc.gov/search">
	<fieldset class="search-form-wrapper local">
		<legend>Search Form Controls</legend>
		<div class="search-form-checkbox">
			<label class="subset"><input type="checkbox" name="subset" checked="checked" value="NIOSH">Search NIOSH</label>
		</div>
		<div class="search-input-wrapper">
			<div class="search-buttons">
				<button class="btn-clear"><span class="sprite-14-close">Cancel</span></button>
				<button class="btn-submit"><span class="sprite-14-search-black">Submit</span></button>
				<input type="submit" value="Submit" style="display:none; visibility:hidden;" /> 
			</div>
			<div class="search-input">
				<label><input type="text" placeholder="SEARCH" name="query" /><span class="hidden">Search The CDC</span></label>
			</div>
		</div>
		<input type="hidden" name="utf8" value="&#x2713;" />
					<input type="hidden" name="affiliate" value="cdc-main" />
			</fieldset>
</form>					</div>
                    <!--
	See the noscript include for modifying the emergency message. DO NOT add it here.
-->
<script>if (typeof page_timing !== 'undefined') { page_timing.emergency_load = Date.now(); }</script>
    				<div class="titlebar">
    					<h2>


<div id="topic-title">
<a href="../../index.htm">The National Institute for Occupational Safety and Health (NIOSH)</a>
</div>

</h2>
    				</div>
    				<!-- emergency -->
<div id="emergencyContainer">
	<!--
	<div class="alert alert-error en">
		<b>Attention!</b> Uncomment this section and place the emergency message here.
	</div>
	<div class="alert alert-error esp">
		<b>&#161;Atenci&#243;n!</b> Elimine el comentario de esta secci&#243;n y colocar el mensaje de emergencia aqu&#237;.
	</div>	
	-->
</div>

<!-- no script -->
<noscript>
	<div class="alert alert-block"> Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: <a href="../../../other/about_cdcgov.html">About CDC.gov</a>.</div>
</noscript>
<script>if (typeof page_timing !== 'undefined') { page_timing.noscript_load = Date.now(); }</script>
     			</div>
    		</header>
    		<div class="container">				
                <div id="content">
					<div class="row">
        				<!-- left nav -->
        				<div id="nav-container" class="hidden-one hidden-two span5">
    						<nav id="left" class="hidden-one hidden-two">
    							



<h3><a href="../../pubs/default.html">NIOSH Publications &#38; Products</a></h3>

<ul id="nav-primary">
<li><a href="../../pubs/all_date_desc_nopubnumbers.html">NIOSH-Issued Publications</a></li>

<li><a href="../../pubs/type.html">Publication Types</a>
<ul>
<li><a href="../../pubs/alerts_date_desc_nopubnumbers.html">Alerts</a></li>

<li><a href="../../pubs/cib_date_desc_nopubnumbers.html">Current Intelligence Bulletins</a></li>

<li><a href="../../pubs/criteria_date_desc_nopubnumbers.html">Criteria Documents</a></li>

<li><a href="../../pubs/fact_date_desc_nopubnumbers.html">Fact Sheets</a></li>

<li>
<a href="../../hhe/default.html">Health Hazard Evaluations (HHEs)</a></li>

<li><a href="../../pubs/hc_date_desc_nopubnumbers.html">Hazard Controls</a></li>

<li><a href="../../pubs/hid_date_desc_nopubnumbers.html">Hazard IDs</a></li>

<li>
<a href="../impact/default.html">NIOSH Impact Sheets</a></li>

<li>
<a href="../../pgms/worknotify/default.html">Worker Health Study Summaries</a></li>

<li><a href="../../pubs/workplace_date_desc_nopubnumbers.html">Workplace Solutions</a></li>

<li>
<a href="../../surveyreports/default.html">Engineering and Physical Hazards Reports</a></li>
</ul>
</li>

<li><a href="../../pubs/order.html">Order Publications</a></li>

<li><a href="http://www2a.cdc.gov/nioshtic-2/default.asp">Search NIOSHTIC-2 Research Database</a></li>

<li><a href="../../docket/default.html">Docket</a></li>

<li><a href="../../review/public/default.html">Documents for Public Review</a></li>

<li><a href="../../review/peer/default.html">Peer Review Agenda</a></li>

<li><a href="../../data/default.html">Databases</a></li>

<li><a href="../../enews/default.html">eNews</a></li>

<li><a href="../../research-rounds/default.html">Research Rounds</a></li>

<li><a href="../../ccc/default.html">Collaborating Centre Connection Newsletter</a></li>

<li><a href="../../fedreg.html">Federal Register Notices</a>
<ul>
<li><a href="../../fedregarchive2007-2010.html">FRN Archive 2007-2010</a></li>

<li><a href="../../fedreg-a.html">FRN Archive 2005-2006</a></li>

<li><a href="../../fedreg-b.html">FRN Archive 2001-2004</a></li>

<li><a href="../../fedreg-c.html">FRN Archive 1996-2000</a></li>
</ul>
</li>

<li id="nav-primary"><a href="../../updates/default.html">Press Releases and Updates</a>
<ul>
<li><a href="../../updates/press10-13.html">Press Release Archives 2010-2013</a></li>

<li><a href="../../updates/press06-09.html">Press Release Archives 2006-2009</a></li>

<li><a href="../../updates/press01-02.html">Press Release Archives 2001-2005</a></li>

<li><a href="../../updates/press98-00.html">Press Release Archives 1998-2000</a></li>

<li><a href="../../updates/press93-97.html">Press Release Archives 1992-1997</a></li>
</ul>
</li>

<li><a href="../../regulations.html">Regulations</a></li>

<li><a href="../../regulatory.html">Regulatory Agenda</a></li>

<li><a href="http://blogs.cdc.gov/niosh-science-blog/">Science Blog</a></li>

<li><a href="../../softpg.html">Software</a></li>

<li><a href="../video/default.html">Video</a></li>
</ul>


    						</nav>
    						<div class="nav-related">
							




    						



<div class="module-typeH topicmedia no-link">
<h4>Follow NIOSH</h4>

<ul class="list-block">
<li>
<div><span class="sprite-24-facebook"><!-- --></span><a href="http://www.facebook.com/NIOSH">Facebook</a></div>
</li>

<li>
<div><span class="sprite-24-flickr"><!-- marker --></span><a href="http://www.flickr.com/photos/NIOSH">Flickr</a></div>
</li>

<li>
<div><span class="sprite-24-pinterest"><!-- marker --></span><a href="http://www.pinterest.com/cdcgov/workplace-safety-and-health/">Pinterest</a></div>
</li>

<li>
<div><span class="sprite-24-twitter"><!-- --></span><a href="http://twitter.com/NIOSH">Twitter</a></div>
</li>

<li>
<div><span class="sprite-24-youtube"><!-- marker --></span><a href="http://www.youtube.com/user/NIOSHSafetyVideos">YouTube</a></div>
</li>
</ul>
</div>

<div class="module-typeA">
<h4><a href="../../homepage.html">NIOSH Homepage</a></h4>

<ul class="list-block">
<li><a href="../../az/a.html">NIOSH A-Z</a></li>

<li><a href="../../topics/index.html">Workplace Safety &#38; Health Topics</a></li>

<li><a href="../../pubs/index.html">Publications and Products</a></li>

<li><a href="../../programs.html">Programs</a></li>

<li class="last"><a href="../../contact/index.html">Contact NIOSH</a></li>
</ul>
</div>


							



							</div>    						    				
        				</div>
        				<div id="featureArea">
    						<div class="span19">
    							




		<div data-picture="" data-alt="NIOSH Logo - Promoting a productive workplace through safety and health research." data-href="">
    <div data-src="/niosh/images/444_niosh_narrowtemp_vp4.png"></div>
    <div data-src="/niosh/images/732_niosh_narrowtemp_vp4.png" data-media="(min-width: 768px)"></div>
    <div data-src="/niosh/images/944_niosh_narrowtemp_vp4.png" data-media="(min-width: 980px)"></div>
    <div data-src="/niosh/images/niosh_narrowtemp_vp4.png" data-media="(min-width: 1200px)"></div>		
	<!--[if (lt IE 9) & (!IEMobile)]>
	<div data-src="/niosh/images/944_niosh_narrowtemp_vp4.png"></div>
	<![endif]-->
	<!-- Fallback content for non-JS browsers. Same img src as the initial, unqualified source element. -->
    <noscript>
		<img src="../../images/944_niosh_narrowtemp_vp4.png" alt="NIOSH Logo - Promoting a productive workplace through safety and health research."/>
    </noscript>
</div>



    						</div>
        				</div>						
    					<div class="breadcrumbs hidden-one span19">
    						


<div class="bread-crumb hidden-one"></div>

    					</div>
						<div class="span19 pagetitle">	
    						    							<div class='syndicate'>
    						    						    							<div class='mSyndicate'>
    																					<h1>Current Intelligence Bulletin 53</h1>
															    						    							</div>
    						    						    							</div>
    												</div>
						<div id="share-bar" class="span19">		
    						<div class="socialmediabar">
								<div class="row">
            						<div class="hidden-one pull-right">
        								            							            							            						</div>	
    								<div class="span8">
    									<div id="socialMediaShareContainer">
	<div class="share_container noLinking">
	 	<a class="share_button_facebook" title="Facebook" href="index.html#"><span class="tp-sr-only">Recommend on Facebook</span><span id="share_facebook" class="facebookRecommend"> </span></a>
	 	<a class="share_button_twitter" title="Twitter" href="index.html#"><span class="tp-sr-only">Tweet</span><span id="share_twitter" class="twitterTweet"> </span></a>
		<a class="share_button" href="index.html#socialMediaShareContainer" ><img src="../../../TemplatePackage/3.0/images/social/addthis-32.png" alt="Share" /><span class="shareButtonEn tp-sr-only" aria-label="Share">Share</span><span class="shareButtonEs tp-sr-only" aria-label="Compartir">Compartir</span></a>
	</div>
</div>

<!-- target anchor for return to top feature in VP1 -->
<a id="content-start" tabindex="-1"></a>
    								</div>
								</div>
    						</div>
    					</div>	
    					<!-- body -->
    					<div id="body" class="span19">
    						<div id="contentArea" >								
        						        																						        						                                                                                            					            						<div class='syndicate'>
            					            					            						<div class='mSyndicate'>
            					            					        							<!-- InstanceBeginEditable name="content-main" -->
<div id="pubno">
<h6 class="pull-right">December 1989</h6>

<h6>DHHS (NIOSH) Publication Number 90-101</h6>
</div>

<h2>Toluene Diisocyanate (TDI) and Toluenediamine (TDA): Evidence of Carcinogenicity</h2>

<div class="pull-right span6" style=" clear: right;">
<div id="onthispage2" class="module-typeF">
<h4>On this Page</h4>

<ul class=" list-bullet">
<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Foreword</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Abstract</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Introduction</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Chemical and Physical Properties</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Production</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Exposure Limits</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Studies of Mutagenicity and Carcinogenicity in Animals</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Human Health Effects</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Conclusions</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Research Needs</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Recommendations</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Guidelines</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Notes</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">References</a></li>

<li><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Appendix</a></li>
</ul>
</div>
</div>

<a id="Foreword" name="Foreword"> <!-- --></a>
<h3>Foreword</h3>

<p>Current Intelligence Bulletins (CIBs) are issued by the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control, Atlanta, Georgia, to disseminate new scientific information about occupational hazards. A CIB may draw attention to a formerly unrecognized hazard, report new data on a known hazard, or disseminate information on hazard control.</p>

<p>CIBs are distributed to representatives of academia, industry, organized labor, public health agencies, and public interest groups, as well as to Federal agencies responsible for ensuring the safety and health of workers.</p>

<p>Copies are available to individuals upon request from the Division of Standards Development and Technology Transfer, NIOSH (Robert A. Taft Laboratories, 4676 Columbia Parkway, Cincinnati, Ohio 45226). We welcome suggestions concerning the content, style, and distribution of these documents.</p>

<p>The purpose of this bulletin is to disseminate new information on the potential carcinogenicity of toluene diisocyanate (TDI) and toluenediamine (TDA). Recent data from studies of chronic toxicity in animals have produced evidence that cancer is associated with exposure to commercial-grade TDI (an 80:20 mixture of 2,4- and 2,6-TDI) and to 2,4-TDA, a reagent used in the manufacture of TDI and a hydrolysis product of TDI. The tumorigenic responses observed in both rats and mice treated with TDI and TDA meet the criteria of the Occupational Safety and Health Administration (OSHA) Cancer Policy for classifying a substance as a potential occupational carcinogen [Title 29 of the <em><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Code of Federal Regulations</a></em>, Section 1990.112]. Because insufficient data exist to evaluate the carcinogenic potential of the other TDI and TDA isomers, NIOSH concludes that occupational exposure to all TDI and TDA isomers should be reduced. NIOSH therefore recommends that all the isomers of TDI and TDA be regarded as potential occupational carcinogens and that occupational exposures be limited to the lowest feasible concentrations. Although the potential for TDI- or TDA-induced cancer in humans has not been determined, reducing exposure to TDI and TDA in the workplace should reduce the risk.</p>

<p>NIOSH urges (1) that producers and users of TDI and TDA disseminate this information to their workers and customers, (2) that professional and trade associations and unions inform their members of the potential hazards of working with TDI and TDA, and (3) that appropriate engineering controls and work practices be used to minimize the exposure of workers. Readers seeking more detailed information on the studies cited in this CIB are encouraged to consult the original publication.</p>

<p><em>[signature]</em><br />
J. Donald Millar, M.D., D.T.P.H. (Lond.)<br />
Assistant Surgeon General<br />
Director, National Institute for<br />
Occupational Safety and Health<br />
Centers for Disease Control</p>

<a id="Abstract" name="Abstract"> <!-- --></a>
<h3>Abstract</h3>

<p>Experimental studies in animals have demonstrated that toluene diisocyanate (TDI) is a carcinogen. When rats and mice were exposed orally to commercial-grade TDI (an 80:20 mixture of 2,4- and 2,6-TDI), tumors were induced in both species. The systemic nature of TDI carcinogenicity was demonstrated by the appearance of tumors at multiple sites (pancreas, liver, skin, mammary glands, and circulatory system). Although not statistically significant, rare brain tumors were found in rats exposed to TDI (two gliomas and one pinealoma). Historical controls have a low incidence of gliomas and no reported incidence of pinealomas.</p>

<p>Experimental studies in animals have also demonstrated that 2,4-toluenediamine (TDA), a hydrolysis product of 2,4-TDI, is a carcinogen. When rats and mice were exposed orally to TDA, tumors were induced in the livers, skin, and mammary glands of both species. The National Institute for Occupational Safety and Health (NIOSH) concludes that the data on carcinogenicity provide sufficient evidence to warrant concern about the potential consequences of occupational exposure to TDI and TDA. The tumorigenic responses observed in both rats and mice treated with either TDI or TDA meet the criteria of the Occupational Safety and Health Administration (OSHA) Cancer Policy for classifying a substance as a potential occupational carcinogen [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">29 CFR 1990</a>]. Although the carcinogenic potential of the other TDI and TDA isomers has not been adequately determined, exposure to all TDI and TDA isomers should be reduced. NIOSH therefore recommends that all the isomers of TDI and TDA be regarded as potential occupational carcinogens and that occupational exposures to TDI and TDA be limited to the lowest feasible concentrations. The potential for TDI- or TDA-induced cancer in humans has not been determined, but the risk of developing cancer should be decreased by reducing exposure to TDI and TDA in the workplace.</p>

<a id="Introduction" name="Introduction"> <!-- --></a>
<h3>Introduction</h3>

<p>The purpose of this bulletin is to disseminate recent information on the potential carcinogenicity of toluene diisocyanate (TDI) and toluenediamine (TDA) to humans. Recent studies of chronic effects in animals have produced evidence that cancer is associated with exposure to commercial-grade TDI (an 80:20 mixture of 2,4- and 2,6-TDI) and to 2,4-TDA, a hydrolysis product of TDI. This bulletin describes the results and implications of those animal studies, presents the known human health effects of TDI and TDA, and suggests guidelines for minimizing occupational exposures.</p>

<a id="Chemical and Physical Properties" name="Chemical and Physical Properties"> <!-- --></a>
<h3>Chemical and Physical Properties</h3>

<p>TDI is manufactured by the reaction of TDA with carbonyl chloride (phosgene). TDI is a colorless-to-amber liquid with a pungent odor. Commercial-grade TDI (which represents more than 95% of TDI industrial usage) is an 80:20 mixture of the two chemical isomers 2,4- and 2,6-TDI. Other chemical and physical properties of commercial-grade TDI are listed in <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Table 1</a>.</p>

<p>TDA is manufactured by nitrating toluene to produce dinitrotoluene, which is then catalytically reduced to TDA. TDA is a colorless solid that tends to darken on storage and exposure to air. Other chemical and physical properties of 2,4-TDA are listed in <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Table 1</a>.</p>

<a id="Production" name="Production"> <!-- --></a>
<h3>Production, Use, and Potential for Occupational Exposure</h3>

<p>TDI is one of the most industrially important diisocyanates. In 1986, 650 million pounds of TDI were produced in the United States, and the demand is expected to rise in the future [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">American Chemical Society 1987</a>]. TDI is widely used in the manufacture of flexible polyurethane foams, elastomers, surface coatings, fibers, sealants, and adhesives. Applications and uses for these products include packaging, insulation materials, upholstery, and shoe soles.</p>

<p>The major route of occupational exposure to TDI is by inhalation of the vapor; exposure may also occur through dermal contact during the handling of liquid TDI. Occupational exposure normally occurs during the production and use of TDI, particularly during the mixing and foaming processes in the polyurethane foam industry. Exposures to airborne TDI may also occur as a result of the melting or burning of polyurethane foams during firefighting. An estimated 34,466 workers were exposed to TDI in the United States during the period 1981 to 1983 <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">[NIOSH 1983</a>]. Representative information on die occurrence of air-borne TDI in the work environment is listed in the <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Appendix</a> .</p>

<p>Chemical and Physical Properties of Commercial-grade TDI<a id="table1note1a" name="table1note1a"> <!-- --></a> (80% 2, 4-TDI and 20% 2,6-TDI)<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">*</a></sup> and <a id="table1note2a" name="table1note2a"> <!-- --></a>2, 4-TDA <sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">**</a></sup></p>


		<div class="rx-row">
    	<div class="module double-rule blocklist" style="clear:right;"><div class="inner"><a id="table1" name="table1"><!-- --></a><h3>Table 1</h3><table border="0" cellpadding="0" cellspacing="0" id="activities" width="100%"><tbody><tr><td>Chemical identity</td><td>TDI</td><td>2,4 TDA</td></tr><tr><td><a id="table1note3a" name="table1note3a"><!-- --></a>CAS<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup> registry number</td><td>26471-62-5</td><td>95-80-7</td></tr><tr><td><a id="table1note4a" name="table1note4a"><!-- --></a>RTECS<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">&#134;</a></sup> accession number</td><td>NQ9490000</td><td>XS9625000</td></tr><tr><td>Synonyms</td><td>Tolylene diisocyanate; isocyanic acid; methyl-metaphenylene isocyanate</td><td>3-Amino-p-toluidine; 1, 3-diamino-4-methyl-benzene; 4-methyl-phenylenediamine; 2,4-diamino-toluene</td></tr><tr><td>Formula</td><td>CH<sub>3</sub>C<sub>6</sub>H<sub>3</sub> (NCO)<sub>2</sub><!-- --></td><td>CH<sub>3</sub>C<sub>6</sub>H<sub>3</sub> (NH<sub>2</sub>)<sub>2</sub><!-- --></td></tr><tr><td>Molecular weight</td><td>174.2</td><td>122.2</td></tr><tr><td>Flash point</td><td>135&#176;C (275&#176;F)</td><td>149&#176;C (300&#176;F)</td></tr><tr><td>Specific gravity of liquid</td><td>1.22 at 25&#176;C (77&#176;F)</td><td>1.045 at 100&#176;C (212&#176;F)</td></tr><tr><td>Boiling point</td><td>250&#176;C (482&#176;F)</td><td>292&#176;C (558&#176;F)</td></tr><tr><td>Freezing/melting point</td><td>20&#176; to 22&#176;C (68&#176; to 72&#176;F)</td><td>99&#176;C (210&#176;F)</td></tr><tr><td>Vapor pressure</td><td>0.05 mm Hg at 25&#176;C (77&#176;F)</td><td>1.0 mm Hg at 107&#176;C (224&#176;F)</td></tr><tr><th>Solubility in:</th></tr><tr><td>Water</td><td>Insoluble</td><td>Soluble</td></tr><tr><td>Alcohol</td><td>Soluble</td><td>Soluble</td></tr><tr><td>Ethyl ether</td><td>Soluble</td><td>Soluble</td></tr><tr><td>Acetone</td><td>Soluble</td><td>Unspecified</td></tr><tr><td>Benzene</td><td>Soluble</td><td>Soluble</td></tr><tr><td>Carbon tetrachloride</td><td>Soluble</td><td>Unspecified</td></tr></tbody></table><p><a id="table1note1" name="table1note1"><!-- --></a><sup>*</sup> Data from <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Upjohn Company [1970]</a>. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><br /><a id="table1note2" name="table1note2"><!-- --></a><sup>**</sup>Data from <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">IARC [1978]</a>. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><br /><a id="table1note3" name="table1note3"><!-- --></a><sup>***</sup>Chemical Abstracts Service. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><br /><a id="table1note4" name="table1note4"><!-- --></a><sup>&#8224;</sup>Registry of Toxic Effects of Chemical Substances [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NIOSH 1987c</a>]. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><!-- --></p></div><!-- --></div>
	</div>
	  

<br />
<a id="TDA" name="TDA"> <!-- --></a>
<h3>TDA</h3>

<p>In 1984, 187 million pounds of TDA were produced in the United States [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">USITC 1984</a>]. Nearly all of the TDA produced is used as part of a mixture (80% 2,4-TDA and 20% 2,6-TDA) for the production of TDI. TDA is also used to make dyes for textiles, leathers, furs, wood, and biological stains; 2,4-TDA is no longer used in the United States in any hair dye formulations [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Hecht 1978</a>].</p>

<p>Workers may be exposed to TDA by dermal contact and, less frequently, by inhalation. Although solid TDA does not normally present an inhalation hazard, it may also be handled and shipped in the molten state, at which time the vapors may present a hazard. An estimated 8,513 workers were exposed to TDA in the United States (luring the period 1981 to 1923 [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NIOSH 1983</a>]. Potential for worker exposure is minimal because more than 99% of the TDA produced is used captively to produce TDI, usually at the same site [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1985</a>]. During the manufacture of TDA, TDA concentrations have ranged from 0.0002 to 0.1241 parts of TDA per million parts (ppm) of air, or 0.001 to 0.620 milligrams per cubic meter (mg/m<sup>3</sup>) [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Ahrenholz and Meyer 1980</a>,<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">1982</a>].</p>

<a id="Exposure Limits" name="Exposure Limits"> <!-- --></a>
<h3>Exposure Limits</h3>

<p>Occupational exposure standards mid recommendations for TDI are based on respiratory irritation and sensitization. The current OSHA permissible exposure limit (PEL) for TDI is 0.005 ppm (0.04 mg/m<sup>3</sup>) as an 8-hr time-weighted average (TWA) concentration and 0.02 ppm (0.15 mg/m<sup>3</sup>) as a short-term exposure limit (STEL) for any 15-minute <a id="note1a" name="note1a"> <!-- --></a>period [54 FR<a href="https://www.cdc.gov/niosh/docs/90-101/default.html"><sup>*</sup></a>2,662 (1989)]. In two separate criteria documents, NIOSH has recommended that exposure to TDI be limited to 0.005 ppm <a id="note2a" name="note2a"> <!-- --></a>(0.036 mg/m<sup>3<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">**</a></sup>) as a TWA concentration for up to a 10-hour workday and a 40-hour workweek, with a ceiling concentration of 0.02 ppm (0.14 mg/m<sup>3</sup>) for any 10-minute period [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NIOSH 1973</a>, <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">1978</a>]. The NIOSH recommended exposure limit (REL) was intended to prevent acute and chronic irritation and sensitization of workers but not to prevent responses in workers who are already sensitized. Available data do not indicate a concentration at which TDI vapor fails to produce adverse reactions in sensitized persons. The American Conference of Governmental Industrial Hygienists (ACGIH) threshold limit value (TLV<sup>®</sup>) for TDI is 0.005 ppm (0.04 mg/m<sup>3</sup>) as an 8-hour TWA concentration and 0.02 ppm (0.15 mg/m<sup>3</sup>) as a STEL [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">ACGIH 1988</a>]. No occupational exposure limit for TDA has been established by OSHA, NIOSH, or ACGIH.</p>

<a id="Studies" name="Studies"> <!-- --></a>
<h3>Studies of Mutagenicity and Carcinogenicity in Animals</h3>

<h4>Mutagenic Effects</h4>

<h5>TDI</h5>

<p>At concentrations of 125 to 500 micrograms/plate, commercial-grade <a id="note3a" name="note3a"> <!-- --></a>TDI<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup> was mutagenic to <em>Salmonella typhimurium</em> strains TA98, TA100, and TA1538 in the presence of a metabolic activator [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Andersen et al. 1980</a>]. Commercial-grade TDI and pure 2,6-TDI were tested for mutagenicity in <em>S. typhimurium</em> strains in the presence and absence of S-9 liver fractions from male Sprague-Dawley rats or Syrian golden hamsters treated with Aroclor 1254 [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1986</a>]. Only after metabolic activation did the commercial-grade TDI and the pure 2,6-TDI cause dose-dependent mutagenic: responses in <em>S. typhimurium</em> strains TA98 and TA100.</p>

<h5>TDA</h5>

<p>2,4-TDA, a hydrolysis product of 2,4-TDI, showed mutagenic activity after metabolic activation in <em>S. typhimurium</em> strains TA98, TA100, and TA1538 [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Ames et al. 1975</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Andersen et al. 1980</a>], whereas 2,6-TDA was mutagenic only in <em>S. typhimurium</em> strains TA98 and TA1538 in the presence of a metabolic activator [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Pienta et al. 1977</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Florin et al. 1980</a>]. 2,5-TDA showed mutagenic activity after metabolic activation in <em>S. typhimurium</em> strain TA1538 [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Ames et al. 1975</a>]. These findings are consistent with previous reports in the literature in which 2,4-TDA induced sex-linked, recessive, lethal mutations when fed to adult male <em>Drosophila melanogaster</em> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Blijleven 1977</a>] and was mutagenic to <em>S. typhimurium</em> strain TA1538 following metabolic activation by S9 preparations from rats and mice treated with ß-naphthoflavone [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Dybing and Thorgeirsson I 1977</a>]. Although 2,4-TDA induced unscheduled DNA synthesis (UDS) in rat hepatocytes, 2,6-TDA did not [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Mirsalis et al. 1982</a>]. Four TDA isomers (2,4-,2,5-,2,6-, and 3,4-TDA) enhanced the transformation of primary hamster embryo cells (HEC) by Symian adenovirus 7 (SA7) and transformed secondary HEC [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Greene and Friedman 1980</a>].</p>

<h4>Carcinogenic Effects</h4>

<h5>TDI</h5>

<p>A comprehensive investigation of TDI carcinogenicity has recently been completed as part of the National Toxicology Program (NTP) [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1986</a>]. In this bioassay, F344/N rats (two groups of 50 males and two groups of 50 females) and B6C3F<sub>1</sub> mice (two groups of 50 males and two groups of 50 females) received commercial-grade TDI in corn oil by gavage 5 days/week for 105 or 106 weeks. Target doses and estimated average doses received for each group of 50 animals are listed in <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Table 2</a>. Control groups of 50 males and 50 females of each species received only corn oil on the same schedule as the other groups. Analyses indicated that the TDI had reacted with the corn oil vehicle and produced unidentified reaction compounds, resulting in gavage concentrations that were actually 77% to 90% of theoretical values. The NTP Peer Review Panel concluded that the reactivity of the TDI with corn oil did not compromise the conclusions of the study and that the TDI-dose-related increases in benign and malignant tumors in rats and mice in the 2-year studies [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1986</a>] fit. The NTP criteria for clear evidence of carcinogenic activity [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1987</a>]. Under the conditions of these gavage studies, commercial-grade TDI caused pancreatic acinar cell adenomas in male rats (p&#60;0.05); pancreatic islet cell adenomas (p<u>&#60;</u>0.01 ), neoplastic nodules of the liver (p&#60;0.05), and mammary gland fibroadenomas (p&#60;0.001) in female rats; and subcutaneous fibromas and fibrosarcomas (combined) in male (p&#60;0.01) and female (p&#60;0.001) rats. The commercial-grade TDI also caused hepatocellular adenomas (p<u>&#60;</u>0.001) as well as hemangiomas or hemangiosarcomas (combined) (p<u>&#60;</u>0.01) in female mice. Commercial-grade TDI was not shown to be carcinogenic for male mice. Although not statistically significant, rare brain tumors were found in male rats exposed to TDI (two gliomas and one pinealoma). Historical controls have a low incidence of gliomas and no reported incidence of pinealomas.</p>

<p>In an inhalation study [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Loeser 1983</a>], groups of 126 male and 126 female Sprague-Dawley CD rats and groups of 120 male and 120 female CD-1 mice were exposed to 0, 0.05, or 0. 15 ppm of commercial-grade TDI for 6 hours/day, 5 days/week over a 2-year period. The results showed no TDI-induced neoplasms in either species. The exposure levels used by Loeser have been criticized because they did not achieve a maximum tolerated dose (i.e., the highest dose that produces some toxic response without compromising an animal's survival for its full expected life span) [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1986</a>]. Thus the doses may not have been sufficient to produce a carcinogenic response.</p>

<p>Target Doses and Estimated Average Doses of <a id="table2note1a" name="table2note1a"> <!-- --></a>TDI Received<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">*</a></sup> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1986</a>]</p>


		<div class="rx-row">
    	<div class="module double-rule blocklist" style="clear:right;"><div class="inner"><a id="table2" name="table2"><!-- --></a><h3>Table 2</h3><table border="0" cellpadding="0" cellspacing="0" id="activities" width="100%"><tbody><tr><td><!-- --></td><th colspan="4">Rats</th><th colspan="4">Mice</th></tr><tr><td><!-- --></td><th colspan="2">Males</th><th colspan="2">Females</th><th colspan="2">Males</th><th colspan="2">Females</th></tr><tr><td>Item</td><td><a id="table2note2a" name="table2note2a"><!-- --></a>I<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">**</a></sup><!-- --></td><td>II</td><td>I</td><td>II</td><td>I</td><td>II</td><td>I</td><td>II</td></tr><tr><td>Target dose, mg/kg per day</td><td>30</td><td>60</td><td>60</td><td>120</td><td>120</td><td>240</td><td>60</td><td>120</td></tr><tr><td>Estimated average dose received, mg/kg per day</td><td>23</td><td>49</td><td>49</td><td>108</td><td>108</td><td>202</td><td>49</td><td>108</td></tr><tr><td>% of target dose received</td><td>77</td><td>82</td><td>82</td><td>90</td><td>90</td><td>84</td><td>82</td><td>90</td></tr></tbody></table><p><a id="table2note1" name="table2note1"><!-- --></a><sup>*</sup>Source: <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP [1986]</a>. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><br /><a id="table2note2" name="table2note2"><!-- --></a><sup>**</sup>Group number. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><!-- --></p></div><!-- --></div>
	</div>
	  

<br />
<h3>TDA</h3>

<p>Isomers of TDI may be converted to the corresponding isomers of toluenediamine (TDA) on contact with water [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Chadwick and Cleveland 1981</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Ulrich 1983</a>]. The carcinogenicity of 2,4-TDA was first reported by [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Ito et al. 1969</a>]. Two groups of 12 male Wistar rats were fed diets containing 0.06% or 0.1% 2,4-TDA for 30 to 36 weeks. A third group of 6 male rats was fed the basal diet alone. Eleven of 12 animals in the group fed 0.06% 2,4-TDA survived for 35 weeks; 7 of these had multiple hepatocellular carcinomas with metastases to the lymph nodes and omentum. Nine of 12 animals in the group fed 0.1% 2,4-TDA survived for 33 weeks, and all 9 had multiple hepatocellular carcinomas. In 6 of the 9 survivors, multiple metastases were present in the lymph nodes, omentum, or epididymis. No tumors were found in any of the controls.</p>

<p>A subsequent National Cancer Institute (NCI) evaluation of 2,4-TDA also showed it to be carcinogenic in F344/N rats and B6C3F<sub>1</sub> mice [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1979</a>]. Groups of 50 male and 50 female F344/N rats were given 2,4-TDA in the diet <em>ad libitum</em> at of 125 or 250 ppm for 40 weeks. Because weight gain was excessively depressed in both treated groups, doses were reduced to 50 and 100 ppm, respectively, and the treatment was continued for additional periods of 63 weeks for the low-dose groups, 39 weeks for the high-dose females. Control groups of 20 male and 20 female rats were fed the basal diet, When incidences of hepatocellular carcinomas and neoplastic nodules were combined, dose-related linear trends occurred in males (p=0.014) and females (p=0.008). In addition, the incidence of mammary gland fibroademonas was dose-related in treated female rats and statistically significant for those on the high dose (P&#60;0.001). Furthermore male rats showed a significantly increased incidence of subcutaneous fibromas (p=0.004).</p>

<p>In another part of the NCI evaluation of TDA [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1979</a>], groups of 50 male and 50 female B6C3F<sub>1</sub> mice received 2,4-TDA in the diet ad libitum at concentrations of 100 or 200 ppm for 101 weeks. Control groups of 20 male and 20 female mice were fed the basal diet. A statistically significant incidence of hepatocellular carcinomas occurred in low-dose (p=0.007) and high-dose (p=0.008) female mice; a statistically significant increase also occurred in the incidence of lymphomas (p&#60;0.001) in the low-dose female mice. No significant increase in tumors occurred in male mice treated with 2,4-TDA.</p>

<p>The carcinogenic potential of 2,5-TDA was tested as its sulfate salt in F344 rats and B6C3F<sub>1</sub> mice [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1978</a>]. Groups of 50 male and 50 female F344 rats were administered 0.06% or 0.2% 2,5-TDA sulfate in their diets <em>ad libitum</em> for 78 weeks followed by 28 to 31 weeks of observation. Groups of 50 male and 50 female B6C3F<sub>1</sub> mice were administered 0.06% or 0.1% 2,5-TDA sulfate in their diets ad libitum for 78 weeks followed by 16 to 19 weeks of observation. All control groups (25 or 50 animals each) were fed the basal diet. [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1978</a>] reported that a statistically significant incidence of lung tumors in high-dose female mice was not considered convincing evidence of a compound-related carcinogenic effect because high-dose and control mice were received in separate shipments mid housed in separate rooms. Other flaws in the experimental design of this bioassay included using different mouse strains for the sub-chronic and chronic toxicity studies and placing the high-dose rats on the 2,5-TDA diet 11 months after the low-dose rats. In addition, low-dose mice began receiving their diet 2 weeks before the control group and 6 months before the high-dose group. Furthermore, the high-dose mice began receiving their diet 2 months after their controls. Under the conditions of this bioassay, 2,5-TDA sulfate was not carcinogenic in F344 rats or B6C3F<sub>1</sub> mice [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1978</a>].</p>

<p>The dihydrochloride salt of the 2,6-isomer of TDA was tested for carcinogenicity in F344/N rats and B6C3F<sub>1</sub> mice [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1980</a>]. Groups of 50 F344/N rats of each sex were given 2,6-TDA dihydrochloride in the diet <em>ad libitum</em> at concentrations of 250 or 500 ppm for 103 weeks; they were then observed for an additional week. Groups of 50 B6C3F<sub>1</sub> mice of each sex were given 2,6-TDA dihydrochloride hi the diet <em>ad libitum</em> at concentrations of 50 or 100 ppm. for 103 weeks; they were then observed for an additional week. A dose-related but not statistically significant incidence of liver tumors occurred in treated male rats and female mice. The investigators concluded that under the conditions of this study, 2,6-TDA dihydrochtoride was not carcinogenic for F344/N rats or B6C3F<sub>1</sub> mice [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1980</a>].</p>

<p>NCI review panels for the 2,5- and 2,6-TDA studies have suggested that both 2,5- and 2,6-TDA be considered for retesting because of deficiencies in experimental design and study conduct and because both compounds were mutagenic in various <em>S. typhimurium</em> strains [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1978</a>, <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">1980</a>].</p>

<h4>Independent Evaluations of TDI and TDA Studies</h4>

<p>The TDI data [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Loeser 1983</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1986</a>] were recently evaluated by the International Agency for Research on Cancer (IARC and the World Health Organization [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">IARC 1986</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">WHO 1987</a>]. The IARC Working Group concluded that the increased incidence of malignant tumors in multiple species was sufficient evidence of the carcinogenicity of TDI in experimental animals. The WHO Task Group concluded that TDI should be treated as a potential human carcinogen and as a known animal carcinogen.</p>

<p><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Clement Associates, Inc. [1982]</a> independently reviewed a 1982 draft of the NTP TDI gavage study [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1986</a>] and the TDI inhalation study [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Loeser 1983</a>] for the International Isocyanate Institute, Inc. Because inhalation is the normal route of exposure to TDI, Clement Associates considered the [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Loeser 1983]</a> study the more useful of the two for assessing the carcinogenic potential of TDI for humans, despite the lack of a maximum tolerated dose in the [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Loeser 1983</a>] study. They further believed that the [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Loeser 1983</a>] study adequately supported the conclusion that TDI was not carcinogenic to rats and mice under the conditions tested.</p>

<p>On the basis of studies in animals [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Ito et al. 1969</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NCI 1979</a>], [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">IARC 1978</a>, <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">1979</a>, <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">1982</a>] concluded that there is sufficient evidence to demonstrate the carcinogenicity of 2,4-TDA. IARC assigns a classification of 2B to chemicals for which there is sufficient evidence of carcinogenicity in animals and inadequate data in humans. In addition, NTP lists 2,4-TDA as a substance "which may reasonably be anticipated to be a carcinogen" because there is sufficient evidence of carcinogenicity in experimental animals even though no evidence exists for humans [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NTP 1985</a>].</p>

<p><a id="Human Health Effects" name="Human Health Effects"><!-- --></a></p>

<h3>Human Health Effects</h3>

<h4>TDI</h4>

<p>TDI is a powerful irritant to the mucous membranes of the eyes and gastrointestinal and respiratory tracts [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Fuchs and Valade 1951</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Swensson et al. 1955</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Upjohn Company 1970</a>]. Direct skin contact with TDI can also cause a marked inflammatory reaction [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Fisher 1967</a>]. The irritant effects on the respiratory tract may progress to a chemical bronchitis characterized by severe bronchospasms [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Williamson 1965</a>]. TDI can also sensitize workers so that they are subject to severe asthma attacks, even when they are reexposed at concentrations below the NIOSH REL [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NIOSH 1973</a>, <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">1978</a>]. No data are available on case reports or epidemiologic: studies of TDI carcinogenicity to humans. However, NIOSH is currently conducting a cohort mortality study of workers exposed to TDI in the polyurethane foam manufacturing industry [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Schnorr et al., in preparation</a>].</p>

<h4>TDA</h4>

<p>Exposure to TDA may result in ataxia, tachycardia, nausea, vomiting, convulsions, and respiratory depression [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">von Oettingen 1941</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Gosselin 1976</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Occupational Health Services, Inc. 1987</a>]. TDA can cause chemical cyanosis (i.e., bluish discoloration of the skin) by converting hemoglobin to methemoglobin [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Air Products and Chemicals, Inc. 1986</a>]. This compound can also cause fatty degeneration of the liver [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">von Oettingen 1941</a>]. Repeated or prolonged contact with TDA can result in sensitization dermatitis, which can cause previously exposed individuals to experience redness and blistering of the skin upon reexposure. TDA can also be irritating to the eyes [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Gosselin 1976</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Occupational Health Services, Inc. 1987</a>]. Data indicate that TDA (unlike TDI) does not induce occupational asthma in workers exposed to polyurethane foams [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Candura and Moscato 1984</a>]. No data are available on case reports or epidemiologic studies of TDA carcinogenicity to humans.</p>

<a id="Conclusions" name="Conclusions"> <!-- --></a>
<h3>Conclusions</h3>

<p>Recent animal studies have demonstrated that commercial-grade TDI and 2,4-TDA are carcinogenic in rats and mice. The pancreas and liver were the principal sites of tumor induction in male and female rats and in female mice treated with TDI. 2,4-TDA induced liver tumors in male and female rats and in female mice, and it induced mammary gland tumors in female rats and mice. Commercial-grade TDI, 2,6-TDI, and four TDA isomers (2,4-, 2,5-, 2,6-, and 3,4-TDA) were mutagenic in various <em>in vitro</em> test systems. No conclusion can be drawn about the carcinogenic potential of 2,5-TDA because of the previously mentioned flaws in the experimental design of the bioassay. No conclusion can be drawn about the carcinogenic potential of 2,6-TDA because the dose-related incidence of liver tumors in treated male rats and female mice was not statistically significant.</p>

<p>Currently, there is no epidemiologic evidence that any isomer of TDI or TDA has induced cancer in exposed workers; however, the positive data in other mammalian species suggest that the potential exists. NIOSH therefore concludes that commercial-grade TDI and 2,4-TDA are potential occupational carcinogens.</p>

<a id="Research Needs" name="Research Needs"> <!-- --></a>
<h3>Research Needs</h3>

<p>The following research needs have been identified:</p>

<ul>
<li>Development of improved sampling and analytical methods (including field validation) for determining airborne TDI and TDA concentrations</li>

<li>Development of automated equipment for preventing worker exposure to TDI and TDA</li>

<li>Identification of less hazardous chemicals that can be used as substitutes for TDI and TDA</li>

<li>Performance of epidemiologic studies of TDI- and TDA-exposed workers</li>

<li>Performance of animal studies that include maximum tolerated doses of 2,5- and 2,6-TDA</li>

<li>Development of a biological monitoring method for TDI and TDA</li>
</ul>

<a id="Recommendations" name="Recommendations"> <!-- --></a>
<h3>Recommendations</h3>

<p>Exposure to TDI and TDA has been shown to produce benign and malignant tumors in rats and mice. NIOSH therefore recommends that all TDI and TDA isomers or mixtures of isomers be regarded as potential occupational <a id="note4a" name="note4a"> <!-- --></a>carcinogens<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">†</a></sup> in conformance with the OSHA Cancer Policy [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">29 CFR 1990</a>]. Though evidence (toes not exist to demonstrate the carcinogenicity of all TDI and TDA isomers, the NIOSH recommendation applies to all of them and to mixtures of these isomers because of the gravity of the potential health effect (cancer) and because TDI and TDA rarely, if ever, occur as pure isomers in the workplace.</p>

<p>The excess cancer risk for workers exposed to TDI and TDA has not yet been quantified, but the probability of developing cancer should be decreased by minimizing exposure. Employers should therefore assess the conditions under which workers may be exposed to TDI and TDA and reduce exposures to the lowest feasible concentrations.</p>

<a id="Guidelines" name="Guidelines"> <!-- --></a>
<h3>Guidelines for Minimizing Worker Exposure to TDI and TDA</h3>

<p>Because TDI and TDA are regarded by NIOSH as potential human carcinogens in the workplace, appropriate engineering and work practice controls should be used to reduce worker exposures to the lowest feasible concentrations. The guidelines and recommendations that follow are general and should be adapted to specific situations as required.</p>

<h3>Exposure Monitoring</h3>

<p>Each employer who manufactures, transports, packages, stores, or uses TDI or TDA in any capacity should determine whether a potential exists for any worker to be exposed to these chemicals.</p>

<h4>Sampling Strategy</h4>

<p>In work areas where exposures may occur, an initial survey should be done to determine the extent of worker exposure. TWA exposures should be determined by collecting samples over a full shift. When the potential for exposure is periodic, short-term samples may be needed to replace or supplement full-shift sampling. Personal sampling (i.e., sampling conducted in the worker's breathing zone) is preferred over area sampling. Area sampling should be substituted only if the results can be used to approximate the worker's exposure. Sampling should be used to identify the sources of emissions so that effective engineering or work practice controls can be instituted.</p>

<p>If the initial survey indicates that no worker is exposed to TDI or TDA, sampling is recommended annually or whenever there are changes in production, process, controls, work practices, or weather conditions that may affect exposure conditions. If work environments are found to contain measurable concentrations of TDI or TDA, workers must wear respirators, and sampling should be conducted weekly until no measurable concentrations of TDI or TDA are noted in two consecutive surveys. Sampling should be conducted again 6 months after the second negative survey. If no measurable concentrations of TDI or TDA are noted after two consecutive biannual surveys, sampling should be conducted annually or whenever changes in production, process, controls, work practices, or weather conditions may affect exposure conditions.</p>

<p>The NIOSH <em>Occupational Exposure Sampling Strategy Manual</em> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Leidel et al. 1977</a>] provides guidance for developing efficient strategies to monitor worker exposure to toxic chemicals. This manual contains information on determining the need for exposure monitoring, the number of samples to be collected, and appropriate sampling times.</p>

<h4>Sampling Methods</h4>

<p>A recommended sampling and analysis method for 2,4-TDI and 2,6-TDI vapors in air is NIOSH Method 2535 [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NIOSH 1987d</a>]. The TDI in a 2- to 170-liter (L) air sample (the volume of air required depends on the anticipated concentration of TDI in the ambient air) is collected at a flow rate of 0.2 to 1 liter/minute (L/min) on reagent-coated glass wool contained in a tube. The reagent N-(4-nitroplienylmethyl) propylamine (frequently called "nitro reagent"), reacts with 2,4- mid 2,6-TDI to form the corresponding ureas. These ureas are extracted from the glass wool with methanol and quantified using high-performance liquid chromatography with ultraviolet spectrometric detection. The lower limit of TDI quantification for this method is 0.003 mg/m<sup>3</sup> for a 100-L air sample. NIOSH Method 2535 may be used for TDI vapors but not for TDI aerosols because aerosol particles probably are not efficiently trapped by the glass-wool plug, and the TDI in the trapped particles will react incompletely with the nitro reagent.</p>

<p>When TDI is present as an aerosol, NIOSH investigators determine its concentration by a modification of Method MDHS 25, developed by the Occupational Medicine and Hygiene Laboratory of Her Majesty's Health and Safety Executive [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Health and Safety Executive 1987</a>]. Air is sampled at a flow rate of 1 L/min through an impinger containing a solution of toluene and 1-(2-methoxyphenyl) piperazine, which reacts with isocyanates to form ureas. The sample is treated in the laboratory with acetic anhydride and then evaporated to dryness. After the residue is dissolved in methanol, the ureas are quantified by liquid chromatography with electrochemical detection. The lower limit of 2,4-TDI quantification for this method is 0.002 mg/m<sup>3</sup> for a 100-L air sample.</p>

<p>A sampling and analysis method for 2,4- or 2,6-TDA is OSHA Method 65 [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Elskamp 1987</a>]. Air is sampled at a flow rate of 1 L/min through a 37-millimeter (mm) glass fiber filter coated with sulfuric acid. Within 10 hours (hr) after sampling, the filter must be transferred to 2 milliliters (mL) of water for storage. The aqueous solution is treated in the laboratory with sodium hydroxide and shaken with toluene; an aliquot of the resulting toluene solution is then treated with heptafluorobutyryl anhydride. The resulting bis(heptafluorobutyryl)amides formed from the 2,4- and 2,6-TDA are quantified by gas chromatography with electron-capture detection. With a 100-L air sample, the lower limit of quantification is 0.00006 mg/m<sup>3</sup> for 2,4- and 2,6-TDA. In this method, 2,4- and 2,6-TDI are positive interferences to the determination of the corresponding diamine.</p>

<p>Although not validated by NIOSH, other published methods may also be suitable for monitoring TDA in the workplace. Some of these methods yield quantitative data for both the diamines and the diisocyanates [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Holdren et al. 1984</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Skarping et al. 1985</a>; <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Dalene et al. 1988</a>], whereas another method quantifies both diamines and diisocyanates as the diamine [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Skarping et al. 1981</a>].</p>

<h3>Controlling Worker Exposure</h3>

<p>Equipment maintenance and worker education are vital aspects of a good occupational health and safety program. Workers must be informed of (1) any materials that may contain or be contaminated with TDI or TDA and (2) the nature of the potential hazard [29 CFR 1910.1200]. Employers must transmit this information by means of a hazard communication program, which is to include container labeling, material safety data sheets (MSDSs), and worker training. Every attempt should also be made to minimize exposure to TDI and TDA by using work practices and controls such as product substitution, closed systems and ventilation, worker isolation, protective clothing and equipment, respiratory protection, decontamination and waste disposal, and medical monitoring. These measures are discussed here briefly.</p>

<h4>Product Substitution</h4>

<p>When feasible, employers should substitute a less hazardous material for TDI or TDA. However, substitutes must be selected with extreme care, and possible adverse health effects should be evaluated first.</p>

<h4>Closed Systems and Ventilation</h4>

<p>Engineering controls should be the principal method for minimizing TDI and TDA exposure in the workplace. Achieving and maintaining reduced concentrations of airborne TDI and TDA depend on adequate engineering controls such as properly constructed and maintained closed-system operations and ventilation systems.</p>

<p>Closed-system operations provide the most effective means for reducing worker exposures to TDI and TDA. Closed systems should be used for producing, storing, transferring, packaging, and processing TDI and TDA. Exhaust ventilation systems should be designed to capture and contain vapors and particulates. Guidance for designing local exhaust ventilation systems can be found in <em>Recommended Industrial Ventilation Guidelines</em> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Hagopian and Bastress 1976</a>], <em>Industrial Ventilation: A Manual of Recommended Practice</em> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">ACGIH 1986</a>], and <em>American National Standard Fundamentals Governing the Design and Operation of Local Exhaust Systems</em> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">ANSI 1979</a>].</p>

<p>Ventilation equipment should be checked at least every 3 months to ensure adequate performance. System effectiveness should also be checked when there are any changes in production, process, or control that might significantly increase TDI and TDA exposures.</p>

<h4>Worker Isolation</h4>

<p>The areas in which TDI and TDA are produced or used should be restricted to workers who are essential to the process or operation. If feasible, these workers should be isolated from direct contact with these chemicals by the use of automated equipment operated from a closed control booth or room. This room should be maintained at greater air pressure than that surrounding the process equipment so that air flows out rather than in. When workers must enter the general work area to perform process checks, adjustments, maintenance, assembly line tasks, and related operations, they should take special precautions such as the use of personal protective equipment.</p>

<h4>Protective Clothing and Equipment</h4>

<p>Workers should be provided with and required to use appropriate personal protective clothing and equipment such as coveralls, footwear, chemical-resistant gloves and goggles, full faceshields, and suitable respiratory equipment. Appropriate coverall materials include Chemrel<sup>®</sup> and Saranex<sup>®</sup>-coated Tyvek<sup>®</sup>; suitable glove materials include butyl rubber, Viton<sup>®</sup>, Teflon<sup>®</sup>, and Silver Shield<sup>®</sup>. Any chemical-resistant clothing that is used should be periodically evaluated to determine its effectiveness in preventing dermal contact. Safety showers and eye wash stations should be located close to operations that involve TDI and TDA.</p>

<h4>Respiratory Protection</h4>

<p>The use of respirators is the least preferred method of controlling worker exposures. Respirators should not be used as the only control for routine operations, but NIOSH recognizes that they may be required to provide protection under certain situations such as implementation of engineering controls, some short-duration maintenance procedures, and emergencies. NIOSH maintains that only the most protective respirators should be used for situations involving carcinogens. These respirators include</p>

<ul>
<li>Any self-contained breathing apparatus with a full facepiece operated in a pressure-demand or other positive-pressure mode, and</li>

<li>Any supplied-air respirator with a full facepiece operated in a pressure-demand or other positive-pressure mode in combination with an auxiliary self-contained breathing apparatus operated in a pressure-demand or other positive-pressure mode.</li>
</ul>

<p>Any respiratory protection program must, at a minimum, meet the requirements of 29 CFR 1910.134. Respirators must be approved by NIOSH and the Mine Safety and Health Administration (MSHA). A complete respiratory protection program should include (1) regular training and medical evaluation of personnel and (2) fit testing, periodic environmental monitoring, and maintenance, inspection, cleaning, and storage of equipment. The program should be evaluated regularly. The following publications contain additional information about selection, fit testing, use, storage, and cleaning of respiratory equipment: <em>Guide to Industrial Respiratory Protection</em> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NIOSH 1987a</a>] and <em>NIOSH Respirator Decision Logic</em> [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">NIOSH 1987b</a>].</p>

<h4>Decontamination and Waste Disposal</h4>

<p>Procedures for decontamination, waste disposal, and transport should be established for TDI- and TDA-contaminated materials or equipment. One of the following solutions should be available at the worksite for cleaning up spills of TDI:</p>

<ul>
<li>4% to 8% ammonium hydroxide, 1% to 2% liquid detergent, and 90% to 95% water, or</li>

<li>20% nonionic surfactant and 80% water [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">III 1980</a>].</li>
</ul>

<p>TDI reacts with either of these decontamination solutions to form polyureas.</p>

<p>The following procedures should be followed if TDI is spilled [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">III 1980</a>]:</p>

<ol>
<li>Absorb the TDI with sawdust or other absorbent material such as vermiculite or ground clay.</li>

<li>Collect the material in an open container and move the container outside.</li>

<li>Add the decontamination solution in a ratio of 2 parts decontaminant to 1 part TDI-contaminated material.</li>

<li>Collect contaminated waste, place it in sealed containers, and dispose of it in accordance with existing regulations of the U.S. Environmental Protection Agency and the U.S. Department of transportation. State and local regulations may supersede Federal regulations if they are more restrictive.</li>
</ol>

<p>The following procedures should be followed if TDA is spilled [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">Air Products and Chemicals, Inc. 1986</a>]:</p>

<ol>
<li>If TDA is in the molten state, evacuate the area until the TDA solidifies.</li>

<li>Spills should be cleaned up by personnel wearing complete body protection.</li>

<li>Using a clean shovel, place the material into disposal containers constructed of corrosion-protected carbon steel or stainless steel.</li>

<li>Waste material may be incinerated or disposed of in accordance with existing regulations of the U.S. Environmental Protection Agency and the U.S. Department of Transportation. State and local regulations may supersede Federal regulations if they are more restrictive.</li>
</ol>

<h4>Medical Monitoring</h4>

<p>A medical monitoring program should be established for early detection and prevention of both the acute and chronic effects of exposure to TDI and TDA. Medical and work histories (including previous exposure to TDI, TDA, or other toxic agents) should be taken for each worker before job placement and updated periodically. The worker's physician should be given information about the adverse health effects of exposure to TDI and TDA and an estimate of the worker's potential for exposure. This information should include results of workplace sampling and a description of any protective devices or equipment the worker is required to use. If workers become sensitized to TDI, they should be removed from potential exposure. Complete medical evaluations should also be performed for each worker upon job transfer or termination. The occurrence of disease or other work-related health effects requires immediate evaluation of primary preventive measures (e.g., industrial hygiene monitoring, engineering controls, and personal protective equipment). Medical personnel should ensure that workers and employers are informed about work-related hazards associated with exposure to TDI and TDA.</p>

<a id="Notes" name="Notes"> <!-- --></a>
<h3>Notes</h3>

<p><a id="note1" name="note1"> <!-- --></a><sup>*</sup>Federal Register. See <a href="https://www.cdc.gov/niosh/docs/90-101/default.html">FR</a> in references <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to text</a>]</em><br />
<a id="note2" name="note2"> <!-- --></a><sup>**</sup>OSHA, NIOSH. and ACGIH may report slightly different metric equivalents because of differences in rounding. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to text</a>]</em><br />
<a id="note3" name="note3"> <!-- --></a><sup>***</sup>Unless otherwise specified, the term "commercial-grade TDI" refers to the 80:20 mixture of the two isomers 2,4- and 2,6-TDI, respectively. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to text</a>]</em><br />
<a id="note4" name="note4"> <!-- --></a><sup>†</sup>"'Potential occupational carcinogen' means any substance, or combination or mixture of substances, which causes an increased incidence of benign and/or malignant neoplasms, or a substantial decrease in the latency period between exposure and onset of neoplasms in humans or in one or more experimental mammalian species as the result of any oral, respiratory, or dermal exposure, or any other exposure which results in the induction of tumors at a site other than the site of administration. This definition also includes any substance which is metabolized into one or more potential occupational carcinogens by mammals." [<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">29 CFR 1990.103</a>] <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to text</a>]</em></p>

<a id="References" name="References"> <!-- --></a>
<h3>References</h3>

<p><a id="ACGIH 1986" name="ACGIH 1986"> <!-- --></a>ACGIH [1986]. Industrial ventilation: a manual of recommended practice. 19th ed. Cincinnati, OH: American Conference of Governmental Industrial Hygienists.</p>

<p><a id="ACGIH 1988" name="ACGIH 1988"> <!-- --></a>ACGIH [1988]. TLV<sup>®</sup>--Threshold limit values and biological exposure indices for 1988-1989. Cincinnati, OH: American Conference of Governmental Industrial Hygienists, p. 36.</p>

<p><a id="Ahrenholz and Meyer 1980" name="Ahrenholz and Meyer 1980"> <!-- --></a>Ahrenholz SH, Meyer CR [1980]. Health hazard evaluation report: Olin Chemical Company, Brandenburg, KY. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, HETA 79-113-728, NTIS No. PB-81-167-819/A02.</p>

<p><a id="Ahrenholz and Meyer 1982" name="Ahrenholz and Meyer 1982"> <!-- --></a>Ahrenholz SH, Meyer CR [1982]. Health hazard evaluation report: Olin (formerly Allied) Chemical Co., Moundsville, WV. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, HETA 81-295-1155, NTIS No. PB-84-150-465/A03.</p>

<p><a id="Air Products and Chemicals, Inc. 1986" name="Air Products and Chemicals, Inc. 1986"> <!-- --></a>Air Products and Chemicals, Inc. [1986]. Toluenediamine--material safety data sheet. Allentown, PA: Air Products and Chemicals, Inc.</p>

<p><a id="Almaguer et al. 1982" name="Almaguer et al. 1982"> <!-- --></a>Almaguer D, Orris P, Kramkowski R [1982]. Health hazard evaluation report: Janesville Products, Brodhead, WI. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, HETA-81-128-1107, NTIS No. PB84-141845.</p>

<p><a id="American Chemical Society 1987" name="American Chemical Society 1987"> <!-- --></a>American Chemical Society [1987]. Key chemicals, toluene diisocyanate. Chemical and Engineering News <em>65</em>(l):12.</p>

<p><a id="Ames et al. 1975" name="Ames et al. 1975"> <!-- --></a>Ames BN, Kammen HO, Yamasaki E [1975]. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc Natl Acad Sci <em>72</em>(6):2423-2427.</p>

<p><a id="Andersen et al. 1980" name="Andersen et al. 1980"> <!-- --></a>Andersen M, Binderup ML, Kiel P, Larsen H, Maxild J [1980]. Mutagenic action of isocyanates used in the production of polyurethanes. Scand J Work Environ Health <em>6</em>:221-226.</p>

<p><a id="Andersson et al. 1982" name="Andersson et al. 1982"> <!-- --></a>Andersson K, Gudehn A, Levin JO, Nilsson CA [1982]. Analysis of gaseous diisocyanates, in air using chemosorption sampling. Chemosphere <em>11</em>:3-10.</p>

<p><a id="ANSI 1979" name="ANSI 1979"> <!-- --></a>ANSI [1979]. American national standard fundamentals governing the design and operation of local exhaust systems. New York, NY: American National Standards Institute, Inc., ANSI Z9.2-1979.</p>

<p><a id="Blijleven 1977" name="Blijleven 1977"> <!-- --></a>Blijleven WG [1977]. Mutagenicity of four hair dyes in Drosophila melanogaster. Mutat Res <em>48</em>:181-186.</p>

<p><a id="Burroughs and Moody 1981" name="Burroughs and Moody 1981"> <!-- --></a>Burroughs GE, Moody PL [1981]. Health hazard evaluation report: Industrial Plastics, Valley City, OH. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, HETA-81-029-1088, NTIS No. PB-83-198390.</p>

<p><a id="Candura and Moscato 1984" name="Candura and Moscato 1984"> <!-- --></a>Candura F, Moscato G [1984]. Do amines induce occupational asthma in workers manufacturing polyurethane foams? Br J Ind Med <em>41</em>:552-553.</p>

<p><a id="CFR" name="CFR"> <!-- --></a>CFR. Code of Federal Regulations. Washington, DC: U.S. Government Printing Office, Office of the Federal Register.</p>

<p><a id="Chadwick and Cleveland 1981" name="Chadwick and Cleveland 1981"> <!-- --></a>Chadwick DH, Cleveland TH [1981]. Organic isocyanates. In: Mark HF, Othmer DF, Overberger CG, Seaborg GT, eds. Kirk Othmer Encyclopedia of Chemical Technology, 3rd edition, Vol. 13. New York, NY: John Wiley and Sons, pp. 789-818.</p>

<p><a id="Chrostek and Cromer 1975" name="Chrostek and Cromer 1975"> <!-- --></a>Chrostek WJ, Cromer JW [1975]. Health hazard evaluation determination report: Trionic Industries, Inc., Harrisburg, PA. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 74-42-168, NTIS No. PB-246-486/A02.</p>

<p><a id="Clement Associates, Inc. 1982" name="Clement Associates, Inc. 1982"> <!-- --></a>Clement Associates, Inc. [1982]. Review of the National Toxicology Program carcinogenesis bioassay of toluene diisocyanate. Arlington, VA: International Isocyanate Institute, Inc.</p>

<p><a id="Dalene et al. 1988" name="Dalene et al. 1988"> <!-- --></a>Dalene M, Mathiasson L, Skarping G, Sango C, Sandstrom JF [1988]. Trace analysis of airborne aromatic isocyanates and related aminoisocyanates and diamines using high-performance, liquid chromatography with ultraviolet and electrochemical detection. J Chromatogr <em>435</em>:469-481.</p>

<p><a id="Daniels et al. 1987" name="Daniels et al. 1987"> <!-- --></a>Daniels W, Almaguer D, Kramkowski R [1987]. Health hazard evaluation report: Sheller Globe (Allen Industries, Inc.), Herrin, IL. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, HETA 86-343-1822.</p>

<p><a id="Diem et al. 1982" name="Diem et al. 1982"> <!-- --></a>Diem JE, Jones RN, Hendrick DJ, Glindmeyer HW, Dharmarajam. V, Butcher BT, Salvaggio JE, Weill H [1982]. Five-year longitudinal study of workers employed in a new toluene diisocyanate manufacturing plant. Am Rev Respir Dis <em>126</em>:420-428.</p>

<p><a id="Dybing and Thorgeirsson I 1977" name="Dybing and Thorgeirsson I 1977"> <!-- --></a>Dybing E, Thorgeirsson I [1977]. Metabolic activation of 2,4-diaminoanisole, a hair dye component. I. Role of cytochrome P-450 metabolism in mutagenicity in vitro. Biochem Pharmacol <em>26</em>:729-734.</p>

<p><a id="Elskamp 1987" name="Elskamp 1987"> <!-- --></a>Elskamp CJ [1987]. Benzidine; 3,3'-dichlorobenzidine; 2,4-toluenediamine; 2,6-toluenediamine. Method 65. Salt Lake City, UT: OSHA Analytical Laboratory.</p>

<p><a id="Fisher 1967" name="Fisher 1967"> <!-- --></a>Fisher AA [1967]. Contact dermatitis. Philadelphia, PA: Lea and Febiger, pp. 134-135.</p>

<p><a id="Florin et al. 1980" name="Florin et al. 1980"> <!-- --></a>Florin I, Rutberg L, Curvall M, Enzell CR [1980]. Screening of tobacco smoke constituents for mutagenicity using the Ames test. Toxicol 15:219-232.</p>

<p><a id="FR" name="FR"> <!-- --></a>45 FR 2,662 [1989]. Air contaminants; final rule. To be codified at 29 CFR 1910.</p>

<p><a id="Fuchs and Valade 1951" name="Fuchs and Valade 1951"> <!-- --></a>Fuchs S, Valade P [1951]. Clinical and experimental study of several cases of intoxication by Desmodur T (toluene diisocyanate 1-2-4 and 1-2-6). Arch Mal Prof <em>12</em>:191-196.</p>

<p><a id="Glass and Thom 1964" name="Glass and Thom 1964"> <!-- --></a>Glass WI, Thom NG [1964]. Respiratory hazards associated with toluene diisocyanate in polyurethane foam production. NZ Med J <em>63</em>:642-647.</p>

<p><a id="Gosselin 1976" name="Gosselin 1976"> <!-- --></a>Gosselin RE [1976]. Clinical toxicology of commercial products. 4th edition. Baltimore, MD: The Williams and Wilkins Co., p. 141.</p>

<p><a id="Greene and Fiedman 1980" name="Greene and Fiedman 1980"> <!-- --></a>Greene EJ, Friedman MA [1980]. In vitro cell transformation screening of 4 toluene diamine isomers. Mutat Res <em>79</em>:363-375.</p>

<p><a id="Gunter 1975" name="Gunter 1975"> <!-- --></a>Gunter BJ [1975]. Health hazard evaluation determination report: Lange Company, Broomfield, CO. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 74-148-239, NTIS No. PB-249-419/A02.</p>

<p><a id="Gunter and Lucas 1975" name="Gunter and Lucas 1975"> <!-- --></a>Gunter BJ, Lucas JB [1975]. Health hazard evaluation determination report: Gates Rubber Company, Denver, CO. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 74-73-233, NTIS No. PB-249-413/A02.</p>

<p><a id="Hagopian and Bastress 1976" name="Hagopian and Bastress 1976"> <!-- --></a>Hagopian JH, Bastress EK [1976]. Recommended industrial ventilation guidelines. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, DHEW (NIOSH) Publication No. 76-162.</p>

<p><a id="Health and Safety Executive 1987" name="Health and Safety Executive 1987"> <!-- --></a>Health and Safety Executive [1987]. Organic isocyanates in air: Methods for the determination of hazardous substances. London, United Kingdom: Health and Safety Executive, MDHS 25.</p>

<p><a id="Hecht 1978" name="Hecht 1978"> <!-- --></a>Hecht A [1978]. Hair dyes--a look at safety and regulation. FDA Consumer, June.</p>

<p><a id="Hervin and Thoburn 1975" name="Hervin and Thoburn 1975"> <!-- --></a>Hervin R, Thoburn TW [1975]. Health hazard evaluation/toxicity determination report: Trans World Airlines Main Overhaul Facility, Kansas City International Airport, Kansas City, MO. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 72-96-237, NTIS No. PB-249-417.</p>

<p><a id="Hobara et al. 1984" name="Hobara et al. 1984"> <!-- --></a>Hobara T, Kobayashi H, Higashihara E, Kawamoto T, Iwamoto S, Shimazu W, Sakai T [1984]. Health hazard by exposure to toluene diisocyanate in the shipyard. Bull Environ Contam Toxicol <em>32</em>:134-139.</p>

<p><a id="Holdren et al. 1984" name="Holdren et al. 1984"> <!-- --></a>Holdren MW, Spicer CW, Riggin RM [1984]. Gas phase reaction of toluene diisocyanate with water vapor. Am Ind Hyg Assoc J <em>45</em>:626-633.</p>

<p><a id="Hosein and Farkas 1981" name="Hosein and Farkas 1981"> <!-- --></a>Hosein HR, Farkas S [1981]. Risk associated with the spray application of polyurethane foam. Am bid Hyg Assoc J <em>42</em>:663-665.</p>

<p><a id="IARC 1978" name="IARC 1978"> <!-- --></a>IARC [1978]. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: some aromatic amines and related nitro compounds, hair dyes, colouring agents and miscellaneous industrial chemicals. IARC Monograph 16. Lyon, France: World Health Organization, International Agency for Research on Cancer, pp. 83-95.</p>

<p><a id="IARC 1979" name="IARC 1979"> <!-- --></a>IARC [1979]. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: polynuclear aromatic compounds; chemicals and industrial processes associated with cancer in humans. IARC Monographs, Volumes 1-20, Supplement 1. Lyon, France: World Health Organization, International Agency for Research on Cancer, pp. 3-5.</p>

<p><a id="IARC 1982" name="IARC 1982"> <!-- --></a>IARC [1982]. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: chemicals, industrial processes and industries associated with cancer in humans. IARC Monographs 1-29, Supplement 4, Appendix 2. Lyon, France: World Health Organization, International Agency for Research on Cancer.</p>

<p><a id="IARC 1986" name="IARC 1986"> <!-- --></a>IARC [1986]. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: some chemicals used in plastics and elastomers. IARC Monograph 39. Lyon, France: World Health Organization, International Agency for Research on Cancer, pp. 287-323.</p>

<p><a id="III 1980" name="III 1980"> <!-- --></a>III [1980]. Recommendations for the handling of toluene diisocyanate (TDI): Bulletin No. 1. New Canaan, CT: International Isocyanate Institute, Inc.</p>

<p><a id="Ito et al. 1969" name="Ito et al. 1969"> <!-- --></a>Ito N, Hiasa Y, Konishi Y, Marugami M [1969]. The development of carcinoma in liver of rats treated with m-toluylenediamine and the synergistic and antagonistic effects with other chemicals. Cancer Res <em>29</em>:1137-1145.</p>

<p><a id="Lee and Bennett 1986" name="Lee and Bennett 1986"> <!-- --></a>Lee SA, Bennett D [1986]. Health hazard evaluation report: Schlegel, Inc., Rochester, NY. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, HETA 84-458-1733, HETA 84-489-1733, NTIS No. PB-87-174-199.</p>

<p><a id="Leidel et al. 1977" name="Leidel et al. 1977"> <!-- --></a>Leidel NA, Busch KA, Lynch JR [1977]. Occupational exposure sampling strategy manual. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, DHEW (NIOSH) Publication No. 77-173, NTIS No. PB-274-792/A07.</p>

<p><a id="Loeser 1983" name="Loeser 1983"> <!-- --></a>Loeser E [1983]. Long-term toxicity and carcinogenicity studies with 2,4/2,6-toluene diisocyanate (80/20) in rats and mice. Toxicol Lett <em>15</em>:71-81.</p>

<p><a id="Markel and Shama 1974" name="Markel and Shama 1974"> <!-- --></a>Markel HL, Shama SK [1974]. Health hazard evaluation report: Whirlpool Corporation, Ft. Smith, Arkansas. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 72-100-121, NTIS No. PB-232-721/A02.</p>

<p><a id="Maxon 1964" name="Maxon 1964"> <!-- --></a>Maxon FC Jr [1964] Respiratory irritation from toluene diisocyanate. Arch Environ Health <em>8</em>:755-758.</p>

<p><a id="Mirsalis et al. 1982" name="Mirsalis et al. 1982"> <!-- --></a>Mirsalis C, Tyson CK, Butterworth BE [1982]. Detection of genotoxic carcinogens in the in vivo-in vitro hepatocyte DNA repair assay. Environ Mutagen <em>4</em>:553-562.</p>

<p><a id="Musk et al. 1982" name="Musk et al. 1982"> <!-- --></a>Musk AW, Peters JM, DiBerardinis L, Murphy RLH [1982]. Absence of respiratory effects in subjects exposed to low concentrations of TDI and MDL J Occup Med <em>24</em>:746-750.</p>

<p><a id="NCI 1978" name="NCI 1978"> <!-- --></a>NCI [1978]. Bioassay of 2,5-toluenediamine sulfate for possible carcinogenicity. Bethesda, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute, TR 126, DHEW (NIH) Publication No. 79-1718.</p>

<p><a id="NCI 1979" name="NCI 1979"> <!-- --></a>NCI [1979]. Bioassay of 2,4-diaminotoluene for possible carcinogenicity. Bethesda, MD: U.S. Department of Health, Education, and Welfare, Public Health Service, National Institutes of Health, National Cancer Institute, TR 162, DHEW (NIH) Publication No. 78-1381.</p>

<p><a id="NCI 1980" name="NCI 1980"> <!-- --></a>NCI [1980]. Bioassay of 2,6-toluenediamine dihydrochloride for possible carcinogenicity. Bethesda, MD, and Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, NTP-80-20, DHHS (NIH) Publication No. 80-1756.</p>

<p><a id="NIOSH 1973" name="NIOSH 1973"> <!-- --></a>NIOSH [1973]. Criteria for a recommended standard: occupational exposure to toluene diisocyanate. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HSM 73-11022.</p>

<p><a id="NIOSH 1978" name="NIOSH 1978"> <!-- --></a>NIOSH [1978]. Criteria for a recommended standard: occupational exposure to diisocyanates. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, DHEW (NIOSH) Publication No. 78-215.</p>

<p><a id="NIOSH 1983" name="NIOSH 1983"> <!-- --></a>NIOSH [1983]. National occupational exposure survey (NOES), 1981-1983: estimated total and female employees, actual observation and trade-named exposure to toluene diisocyanate and methyl benzene diamine. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, Division of Surveillance, Hazard Evaluations and Field Studies, Surveillance Branch. Unpublished data base.</p>

<p><a id="NIOSH 1987a" name="NIOSH 1987a"> <!-- --></a>NIOSH [1987a]. Guide to industrial respiratory protection. Morgantown, WV: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 87-116.</p>

<p><a id="NIOSH 1987b" name="NIOSH 1987b"> <!-- --></a>NIOSH [1987b]. NIOSH respirator decision logic. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 87-108.</p>

<p><a id="NIOSH 1987c" name="NIOSH 1987c"> <!-- --></a>NIOSH [1987c]. Registry of toxic effects of chemical substances: 1985-86 edition. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control., National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 87-114.</p>

<p><a id="NIOSH 1987d" name="NIOSH 1987d"> <!-- --></a>NIOSH [1987d]. Toluene-2,4-diisocyanate NIOSH Method 2535. In: Second supplement to NIOSH manual of analytical methods, 3rd edition. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 84-100.</p>

<p><a id="NTP 1985" name="NTP 1985"> <!-- --></a>NTP [1985]. Fourth annual report on carcinogens: summary. Washington, DC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Toxicology Program, NIH Publication No. NTP 85-002, pp. 69-70.</p>

<p><a id="NTP 1986" name="NTP 1986"> <!-- --></a>NTP [1986]. NTP technical report on the toxicology and carcinogenesis studies of commercial grade 2,4(80%)- and 2,6 (20%)-toluene diisocyanate (CAS No. 26471-62-5) in F344/N rats and B6C3F1 mice (gavage studies). Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Toxicology Program, NTP TR 25 1, NIH Publication No. 86-2507.</p>

<p><a id="NTP 1987" name="NTP 1987"> <!-- --></a>NTP [1987]. NTP technical report on the toxicology and carcinogenesis studies of methyl carbamate (CAS No. 598-55-0) in F344/N rats and B6C3F1 mice (gavage studies). Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Toxicology Program, NTP TR 328, NIH Publication No. 88-2584.</p>

<p><a id="Occupational Health Services, Inc. 1987" name="Occupational Health Services, Inc. 1987"> <!-- --></a>Occupational Health Services, Inc. [1987]. Toluenediamine material safety data sheet. New York, NY: Occupational Health Services, Inc. Peters JM, Murphy RLH, Pagnotto LD, Van Ganse WF [1968]. Acute respiratory effects in workers exposed to low levels of toluene diisocyanate (TDI). Arch Environ Health <em>16</em>:642-647.</p>

<p><a id="Peters et al. 1969" name="Peters et al. 1969"> <!-- --></a>Peters JM, Murphy RLH, Ferris BG Jr. [1969]. Ventilatory function in workers exposed to low levels of toluene diisocyanate: a six-month follow-up. Br J Ind Med <em>26</em>:115-120.</p>

<p><a id="Pienta et al. 1977" name="Pienta et al. 1977"> <!-- --></a>Pienta RJ, Mukund JS, Lebherz WB III, Andrews AW [1977]. Correlation of bacterial mutagenicity and hamster cell transformation with tumorigenicity induced by 2,4-toluenediamine. Cancer Lett <em>3</em>:45-52.</p>

<p><a id="Porter et al. 1975" name="Porter et al. 1975"> <!-- --></a>Porter CP, Higgins RL, Scheel LD [1975]. A retrospective study of clinical, physiologic and immunologic changes in workers exposed to toluene diisocyanate. Am Ind Hyg Assoc J <em>36</em>:159-168.</p>

<p><a id="Roper et al. 1975" name="Roper et al. 1975"> <!-- --></a>Roper CP, Cromer JW Jr. [1975]. Health hazard evaluation/toxicity determination report: General Tire and Rubber Company, Marion, IN. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 74-118-218, NTIS No. PB-249398.</p>

<p><a id="Schnorr et al. in preparation" name="Schnorr et al. in preparation"> <!-- --></a>Schnorr TM, Egilman D, Boeniger MF [in preparation]. Mortality study of workers exposed to toluene diisocyanate. Cincinnati, OH: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Institute for Occupational Safety and Health, Division of Surveillance, Hazard Evaluations, and Field Studies, Industrywide Studies Branch.</p>

<p><a id="Skarping et al. 1981" name="Skarping et al. 1981"> <!-- --></a>Skarping G, Sango C, Smith B [1981]. Trace analysis of isocyanates in industrial atmospheres using gas chromatography and electron-capture detection. J Chromatogr <em>208</em>:313-321.</p>

<p><a id="Skarping et al. 1985" name="Skarping et al. 1985"> <!-- --></a>Skarping G, Penman L, Sango G, Mathiasson L, Dalene M [1985]. Capillary gas chromatographic method for the determination of complex mixtures of isocyanates and amines. J Chromatogr <em>346</em>:191-204.</p>

<p><a id="Swensson et al. 1955" name="Swensson et al. 1955"> <!-- --></a>Swensson A, Holmquist CE, Lundgren KD [1955]. Injury to the respiratory tract by isocyanates used in making lacquers. Br J Ind Med <em>12</em>:20-33.</p>

<p><a id="Ulrich 1983" name="Ulrich 1983"> <!-- --></a>Ulrich H [1983]. Urethane polymers. In: Mark HF, Othmer DF, Overberger CG, Seaborg GT, eds. Kirk Othmer Encyclopedia of Chemical Technology. 3rd edition, Vol. 23. New York, NY: John Wiley and Sons, pp. 576-608.</p>

<p><a id="Upjohn Company 1970" name="Upjohn Company 1970"> <!-- --></a>Upjohn Company [1970]. Urethanes engineering, medical control and toxicologic considerations. Kalamazoo, MI: Upjohn Company, Technical Bulletin-105.</p>

<p><a id="USITC 1984" name="USITC 1984"> <!-- --></a>USITC [1984]. Synthetic organic chemicals: United States production and sales (Investigation No. 332-135). Washington, DC: United States International Trade Commission, Publication 1745, pp. 25-26.</p>

<p><a id="Vandervort and Shama 1973" name="Vandervort and Shama 1973"> <!-- --></a>Vandervort R, Shama SK [1973]. Health hazard evaluation determination report: King Seely Thermos Company, Macomb, IL. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 73-30-90, NTIS No. PB-232-565/A02.</p>

<p><a id="von Oettingen 1941" name="von Oettingen 1941"> <!-- --></a>von Oettingen WF [1941]. The aromatic amino and nitro compounds: their toxicity and potential dangers. A review of the literature. Federal Security Agency, U.S. Public Health Service, Public Health Bulletin No. 271, p. 61.</p>

<p><a id="Walworth and Virchow 1959" name="Walworth and Virchow 1959"> <!-- --></a>Walworth HT, Virchow WE [1959]. Industrial hygiene experiences with toluene diisocyanate. Am Ind Hyg Assoc J <em>20</em>:205-210.</p>

<p><a id="Wegman et al. 1974" name="Wegman et al. 1974"> <!-- --></a>Wegman DH, Pagnotto LD, Fine LJ, Peters JM [1974]. A dose-response relationship in TDI workers. J Occup Med <em>16</em>:258-260.</p>

<p><a id="Wegman et al. 1982" name="Wegman et al. 1982"> <!-- --></a>Wegman DH, Musk AW, Main DM, Pagnotto LD [1982]. Accelerated loss of FEV-1 in polyurethane production workers: a four-year prospective study. Am J Ind Med <em>3</em>:209-215.</p>

<p><a id="White and Wegman 1978" name="White and Wegman 1978"> <!-- --></a>White GL, Wegman DH [1978]. Health hazard evaluation determination report: Lear Siegler, Inc., Marblehead, MA. Cincinnati, OH: U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, HHE 78-68-546, NTIS No. PB-81-150-534/A03.</p>

<p><a id="White et al. 1980" name="White et al. 1980"> <!-- --></a>White WG, Sugden E, Morris MJ, Zatata E [1980]. Isocyanate-induced asthma in a car factory. Lancet <em>i</em>:56-760.</p>

<p><a id="WHO 1987" name="WHO 1987"> <!-- --></a>WHO [1987]. Environmental Health Criteria No. 75: Toluene Diisocyanate. International Programme on Chemical Safety (IPCS). Geneva, Switzerland: World Health Organization.</p>

<p><a id="Williamson 1965" name="Williamson 1965"> <!-- --></a>Williamson KS [1965]. Studies of diisocyanate workers (2). Trans Assoc Ind Med Off <em>15</em>:29-35.</p>

<p>Concentrations of Toluene Diisocyanate (TDI) in the <a id="Appendixnote1a" name="Appendixnote1a"> <!-- --></a>Workplace<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">*</a></sup></p>


		<div class="rx-row">
    	<div class="module double-rule blocklist" style="clear:right;"><div class="inner"><a id="Appendix" name="Appendix"><!-- --></a><h3>Appendix</h3><table border="0" cellpadding="0" cellspacing="0" id="activities" width="100%"><tbody><tr><td><!-- --></td><th colspan="3">Air <a id="Appendixnote2a" name="Appendixnote2a"><!-- --></a>concentration<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">**</a></sup><!-- --></th></tr><tr><th>Source of exposure and<br />year of study</th><th>No. of samples</th><th>Mean or range<br />of means (mg/m<sup>3</sup>)</th><th>Reference</th></tr><tr><td>TDI production:<br />1956-1974<br />1973-1978</td><td><br />Unspecified<br />1949</td><td><br />&lt;0.028-0.43<br /><a id="Appendixnote3a" name="Appendixnote3a"><!-- --></a>0.0142<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td><br />Porter et al. [1975]<br />Diem et al. [1982]</td></tr><tr><th colspan="4">Polyurethane<br />foam production<br />(pouring and molding):</th></tr><tr><td>1955</td><td>&gt;10</td><td>0.28-2.71</td><td>Walworth and Virchow [1959]</td></tr><tr><td>1956</td><td>&gt;130</td><td><a id="Appendixnote4a" name="Appendixnote4a"><!-- --></a>ND<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">&#134;</a></sup>-3.13</td><td>Walworth and Virchow [1959]</td></tr><tr><td>1957</td><td>&gt;20</td><td>ND-19.95</td><td>Walworth and Virchow [1959]</td></tr><tr><td>1964</td><td>28</td><td>0.054.239</td><td>Glass and Thom [1964]</td></tr><tr><td>1965</td><td>Unspecified</td><td>0.142-0.214</td><td>Peters et al. [1968]</td></tr><tr><td>1966</td><td>24</td><td>ND-0.214</td><td>Peters et al. [1969]</td></tr><tr><td>1967</td><td>8</td><td>ND-0.085</td><td>Peters et al. [1969]</td></tr><tr><td>1972</td><td>Unspecified</td><td>0.142-0.085</td><td>Wegman et al. [1974]</td></tr><tr><td>1972-1974</td><td>286</td><td>0.142-0.036</td><td>Wegman et al. [1982]</td></tr><tr><td>1974-1976</td><td>138</td><td>0.007-0.050</td><td>Wegman et al. [1982]</td></tr><tr><td>1973</td><td>11</td><td>0.005-0.007<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Vandervort and Shama [1973]</td></tr><tr><td>1973</td><td>21</td><td>0.053-0.356</td><td>Markel and Shama [1974]</td></tr><tr><td>1973</td><td>418</td><td>0.009-0.016<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Musk et al. [1982]</td></tr><tr><td>1974 (2,4-isomer)</td><td>6</td><td>0.021<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Chrostek and Cromer [1975]</td></tr><tr><td>1974</td><td>540</td><td>0.010-0.011<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Musk et al. [1982]</td></tr><tr><td>1974</td><td>8</td><td>0.123<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Gunter and Lucas [1975]</td></tr><tr><td>1975</td><td>6</td><td>0.379<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Gunter [1975]</td></tr><tr><td>1975</td><td>10</td><td>0.004-0.017<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Roper and Cromer [1975]</td></tr><tr><td>1975</td><td>624</td><td>0.006-0.011<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Musk et al. [1982]</td></tr><tr><td>1976</td><td>461</td><td>0.003-0.009<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Musk et al. [1982]</td></tr><tr><td>1978</td><td>21</td><td>0.036-0.041<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>White and Wegman [1978]</td></tr><tr><td>1981</td><td>12</td><td>0.002-0.004<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Burroughs and Moody [1982]</td></tr><tr><td>1981</td><td>7</td><td>0.003<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Almaguer et al. [1982]</td></tr><tr><td>1981</td><td>4</td><td>0.054-0.140</td><td>Andersson et al. [1982]</td></tr><tr><td>1984 (2, 4-isomer)</td><td>20</td><td>0.007-0.011<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Lee and Bennett [1986]</td></tr><tr><td>1984 (2, 6-isomer)</td><td>20</td><td>0.004-0.004<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Lee and Bennett [1986]</td></tr><tr><td>Polyurethane foam spray application: 1979</td><td>12</td><td>0.121-0.199<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Hosein and Farkas [1981]</td></tr><tr><td>Polyurethane spray paint use: 1960, 1974</td><td>3, 13</td><td>0.712, 0.015-0.02<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Maxon [1964] Hervin and Thoburn [1975]</td></tr><tr><td>Heating of polyurethane foam: 1987</td><td>6</td><td>0.015<sup><a href="https://www.cdc.gov/niosh/docs/90-101/default.html">***</a></sup><!-- --></td><td>Daniels et al. [1987]</td></tr><tr><td>TDI release from insulation (1 meter from polyurethane floor in a ship&#39;s hold): 1983</td><td>6</td><td>0.138</td><td>Hobara et al. [1984]</td></tr><tr><td>TDI release from coated fabric (in a seat cover factory): 1979</td><td>Unspecified</td><td>0.002-0.021</td><td>White et al. [1980]</td></tr></tbody></table><p><a id="Appendixnote1" name="Appendixnote1"><!-- --></a><sup>*</sup>Unidentified mixtures primarily containing 2, 4- and 2, 6-TDI (unless the particular isomer is listed). <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><br /><a id="Appendixnote2" name="Appendixnote2"><!-- --></a><sup>**</sup>Concentrations are reported as milligrams of TDI per cubic meter of ambient air (mg/m<sup>3</sup>) in work areas, except for those figures marked with an asterisk (*), which were personal samples. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><br /><a id="Appendixnote3" name="Appendixnote3"><!-- --></a><sup>***</sup>Personal samples. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><br /><a id="Appendixnote4" name="Appendixnote4"><!-- --></a><sup>&#8224;</sup>None detected. <em>[<a href="https://www.cdc.gov/niosh/docs/90-101/default.html">return to table</a>]</em><!-- --></p></div><!-- --></div>
	</div>
	  

<!-- InstanceEndEditable --><!-- /end .main-inner -->
<div id="linkPolicy"><!-- --></div>

<!-- /end #content-main-->             					            					            						</div>
            					            					            						</div>
            													        						                                                                                        						                                                                								<!-- Related Nav Area -->
								<div class="nav-related hidden-three hidden-four">
									




									



<div class="module-typeH topicmedia no-link">
<h4>Follow NIOSH</h4>

<ul class="list-block">
<li>
<div><span class="sprite-24-facebook"><!-- --></span><a href="http://www.facebook.com/NIOSH">Facebook</a></div>
</li>

<li>
<div><span class="sprite-24-flickr"><!-- marker --></span><a href="http://www.flickr.com/photos/NIOSH">Flickr</a></div>
</li>

<li>
<div><span class="sprite-24-pinterest"><!-- marker --></span><a href="http://www.pinterest.com/cdcgov/workplace-safety-and-health/">Pinterest</a></div>
</li>

<li>
<div><span class="sprite-24-twitter"><!-- --></span><a href="http://twitter.com/NIOSH">Twitter</a></div>
</li>

<li>
<div><span class="sprite-24-youtube"><!-- marker --></span><a href="http://www.youtube.com/user/NIOSHSafetyVideos">YouTube</a></div>
</li>
</ul>
</div>

<div class="module-typeA">
<h4><a href="../../homepage.html">NIOSH Homepage</a></h4>

<ul class="list-block">
<li><a href="../../az/a.html">NIOSH A-Z</a></li>

<li><a href="../../topics/index.html">Workplace Safety &#38; Health Topics</a></li>

<li><a href="../../pubs/index.html">Publications and Products</a></li>

<li><a href="../../programs.html">Programs</a></li>

<li class="last"><a href="../../contact/index.html">Contact NIOSH</a></li>
</ul>
</div>


								</div>
    							<!-- Persistent Content Area -->
    							<div id="content-secondary">
                                    



            						



    							</div><!-- /end #content-secondary -->
    						</div><!-- /end #contentArea -->
    					</div><!-- /end body -->	
					</div>
					<div class="row">
						<div class="span24 visible-one">
																											</div>
					</div>
					<div class="row">
						<div class="span24">
                            <div id="plugin-legend" class="pluginOff">
	<h5>File Formats Help:</h5><span><a href="../../../Other/plugins/index.html">How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?</a></span>
	<ul>
		<li class="plugin-pdf"><a href="../../../Other/plugins/index.html#pdf"><span class="sprite-16-pdf">Adobe PDF file</span></a></li>
		<li class="plugin-ppt"><a href="../../../Other/plugins/index.html#ppt"><span class="sprite-16-ppt">Microsoft PowerPoint file</span></a></li>
		<li class="plugin-word"><a href="../../../Other/plugins/index.html#doc"><span class="sprite-16-word">Microsoft Word file</span></a></li>
		<li class="plugin-excel"><a href="../../../Other/plugins/index.html#xls"><span class="sprite-16-excel">Microsoft Excel file</span></a></li>
		<li class="plugin-wmv"><a href="../../../Other/plugins/index.html#wmv"><span class="sprite-16-wmv">Audio/Video file</span></a></li>
		<li class="plugin-qt"><a href="../../../Other/plugins/index.html#qt"><span class="sprite-16-qt">Apple Quicktime file</span></a></li>
		<li class="plugin-real"><a href="../../../Other/plugins/index.html#ram"><span class="sprite-16-rp">RealPlayer file</span></a></li>
		<li class="plugin-text"><a href="../../../Other/plugins/index.html#text"><span class="sprite-16-txt">Text file</span></a></li>
		<li class="plugin-zip"><a href="../../../Other/plugins/index.html#zip"><span class="sprite-16-zip">Zip Archive file</span></a></li>
		<li class="plugin-sas"><a href="../../../Other/plugins/index.html#sas"><span class="sprite-16-sas">SAS file</span></a></li>
		<li class="plugin-epub"><a href="../../../Other/plugins/index.html#epub"><span class="sprite-16-ebook">ePub file</span></a></li>
		<li class="plugin-ris"><a href="../../../Other/plugins/index.html#ris"><span class="sprite-16-ris">RIS file</span></a></li>
	</ul>
</div>
						</div>
					</div>
					<!-- date stamp -->
					<div id="datestamp" class="row" itemscope="itemscope" itemtype="http://schema.org/WebPage">
						<div class="span24">
    						<ul> 
            					            						<li class="last-reviewed">Page last reviewed: <span itemprop="lastReviewed">June 6, 2014</span></li>
            													            					            						<li class="last-updated">Page last updated: <span itemprop="dateModified">June 6, 2014</span></li>
            					        							<li class="content-source">Content source:
    									



<ul>
<li class="" itemprop="sourceOrganization" itemscope="itemscope" itemtype="http://schema.org/Organization"><a href="../../homepage.html">National Institute for Occupational Safety and Health</a> Education and Information Division</li>
</ul>


        							</li>
									



    						</ul>
						</div>
					</div>					
				</div><!-- /end #content -->
			</div><!-- /.container for content -->					
			<!-- footer -->
				<footer id="footer" class="cdcSlimFooter">
	
 <!-- include eng footerSubSocialMedia.html -->
<div class="socialMedia">
	<div class="container">
		<nav class="followcdc">
			<ul>
				<li><a href="../../../Other/emailupdates.1.html"><span class="sprite-24-govd"></span><span class="tp-sr-only">Email</span></a></li>
				<li><a href="https://www.facebook.com/CDC" target="_blank"><span class="sprite-24-facebook"></span><span class="tp-sr-only">Recommend</span></a></li>
				<li><a href="https://twitter.com/CDCgov" target="_blank"><span class="sprite-24-twitter"></span><span class="tp-sr-only">Tweet</span></a></li>
				<li><a href="https://www.youtube.com/user/CDCstreamingHealth" target="_blank"><span class="sprite-24-youtube"></span><span class="tp-sr-only">YouTube</span></a></li>
				<li><a href="https://www.instagram.com/CDCgov/" target="_blank"><span class="sprite-24-instagram"></span><span class="tp-sr-only">Instagram</span></a></li>
			</ul>
		</nav>
		<nav class="cdcmedia">
			<ul>
				<li><a href="https://www2c.cdc.gov/podcasts"><span class="sprite-24-listen"></span><span class="tp-sr-only">Listen</span></a></li>
				<li><a href="../../../cdctv.1.html"><span class="sprite-24-watch"></span><span class="tp-sr-only">Watch</span></a></li>
				<li><a href="https://www2c.cdc.gov/podcasts/rss.asp"><span class="sprite-24-rss"></span><span class="tp-sr-only">RSS</span></a></li>
			</ul>
		</nav>
	</div>
</div>
 <!-- /include eng footerSubSocialMedia.html -->

	<div class="container">
		<div class="cdcLinks">
			<div class="container">
				<ul>
					
<!-- include eng footerSubCdcLinks.html-->
<li>
	<nav>
		<h6 class="hidden-four hidden-three">ABOUT <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../../about/default.htm">About CDC</a></li>
			<li><a href="https://jobs.cdc.gov">Jobs</a></li>
			<li><a href="../../../funding.1.html">Funding</a></li>
		</ul>
	</nav>
</li>
<li>
	<nav>
		<h6 class="hidden-four hidden-three">LEGAL <span class="icon-plus visible-one pull-right"></span></h6>
		<ul class="hidden-one">
			<li><a href="../../../Other/policies.html">Policies</a></li>
			<li><a href="../../../Other/privacy.html">Privacy</a></li>
			<li><a href="../../../od/foia.1.html">FOIA</a></li>
			<li><a href="../../../eeo/nofearact/index.htm">No Fear Act</a></li>
			<li><a href="https://oig.hhs.gov" class="no-link">OIG</a></li>
		</ul>
	</nav>
</li>
<!--/ include eng footerSubCdcLinks.html-->

				</ul>
			</div>
		</div>
		<div class="cdcContact">
			<div class="container">
				<ul>
					<li class="local-contact">
						
 <!-- include eng footerSubGlobalContact1.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="address" itemscope="itemscope" itemtype="https://schema.org/PostalAddress">
			<span itemprop="streetAddress">1600 Clifton Road</span>
			<span itemprop="addressLocality">Atlanta</span>,
			<span itemprop="addressRegion">GA</span>
			<span itemprop="postalCode">30329-4027</span>
			<span itemprop="addressCountry">USA</span>
		</span><br />
		<span class="value" itemprop="telephone">800-CDC-INFO (800-232-4636)</span>,
		<span class="value" itemprop="telephone">TTY: 888-232-6348</span><br />
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://wwwn.cdc.gov/dcs/RequestForm.aspx" class=" default no-link">Email CDC-INFO</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact1.html -->

					</li>
					<li class="contact">
						
 <!-- include eng footerSubGlobalContact2.html -->
<section>
	<address class="address" itemscope="itemscope" itemtype="https://schema.org/Organization">
		<span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.hhs.gov" class="no-link">U.S. Department of Health & Human Services</a></span>
		</span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
        	<span itemprop="url"><a href="https://www.hhs.gov/open" class="no-link">HHS/Open</a></span>
        </span><br />
        <span class="value" itemprop="contactPoint" itemscope="itemscope" itemtype="https://schema.org/ContactPoint">
			<span itemprop="url"><a href="https://www.usa.gov/" class="no-link">USA.gov</a></span>
		</span>
	</address>
</section>
 <!-- /include eng footerSubGlobalContact2.html -->

					</li>
				</ul>
			</div>
		</div>
	</div>
</footer>			<!-- /#footer -->
			<div id="totop" class="off visible-one">Top</div>
        </div>
		<script>page_timing.libs_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/libs.min.js@3.2.1.7"></script><script>page_timing.libs_end = Date.now();page_timing.core_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/core.min.js@3.2.1.7"></script><script>page_timing.core_end = Date.now();</script><!-- Start Site Settings Overrides -->
<script>
CDC.Constants.set("flexSliderVideoDomains", ['youtube.com','ytimg.com','vimeocdn.com'], 'es');
	CDC.Global.settings.includeCDCInBreadCrumbBar=false;
</script>
<!-- End Site Settings Overrides --><script>page_timing.app_start = Date.now();</script><script src="../../../TemplatePackage/3.0/js/app.min.js@3.2.1.7"></script><script>page_timing.app_end = Date.now();</script>		
		        			<!-- Begin Survey scripts -->
<script src="../../../JScript/foresee/foresee-trigger.js"></script>
<script src="../../../JScript/foresee-variables.js"></script>
<!-- End Survey scripts -->
			
            <script>if (typeof page_timing !== 'undefined') { page_timing.metrics_start = Date.now(); }</script>
<!-- xxxxxxxxxxxxxxxxxx METRICS code begins here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<div id="metrics">

<!-- Begin Google DAP inclusion -->
<script type="text/javascript" id="_fed_an_ua_tag" src="../../../JScript/metrics/google/Universal-Federated-Analytics-Min.js@agency=HHS&amp;subagency=CDC"></script>
<!-- End Google DAP inclusion -->

<!-- Begin Template Package Custom Interactions -->
<script type="text/javascript" src="../../../JScript/metrics/rd_custom_interactions.js"></script>
<!-- End Template Package Custom Interactions -->

<!-- SiteCatalyst code version: H.21. -->
<script src="../../../JScript/metrics/topic_levels.js"></script>
<script src="../../../JScript/metrics/s_code_v21_cdcgov.js"></script>
<script>

	enquire.register(CDC.Global.selectors.vp1, function() {
		s.prop49 = 1;
	});
	enquire.register(CDC.Global.selectors.vp2, function() {
		s.prop49 = 2;
	});
	enquire.register(CDC.Global.selectors.vp3, function() {
		s.prop49 = 3;
	});
	enquire.register(CDC.Global.selectors.vp4, function() {
		s.prop49 = 4;
	});

            
            


s.pageName=document.title; 
s.channel="NIOSH";

siteCatalyst.setLevel1("NIOSH"); 
siteCatalyst.setLevel2("NIOSH Docs"); 




            
                        
            s.prop2=window.location.href;
s.prop26=document.title;
s.prop30=document.title;
s.prop31=window.location.href;
s.prop46=window.location.href;
s.server=window.location.hostname;

// Update the level variables here.
updateVariables(s);

/************* DO NOT ALTER ANYTHING BELOW THIS LINE ! **************/
var s_code=s.t();



if(s_code) {
	document.write(s_code);
}



if (document.location.protocol) {


	var cookieManagment = {
		getUuid : function (strPrefix) {
			strPrefix = strPrefix || "";
			var d = new Date();
			var seconds = Math.round(d.getTime() / 1000);
			return strPrefix + Math.floor((1 + Math.random()) * 0x10000).toString(16).substring(1) + "-" + seconds.toString();
		},
		setCookie : function (cname, cvalue, exdays, domain) {
			domain = domain || ".cdc.gov";
			var d = new Date();
			d.setTime(d.getTime() + (exdays*24*60*60*1000));
			var expires = "expires="+ d.toUTCString();
			document.cookie = cname + "=" + cvalue + ";" + expires + ";domain=" + domain + ";path=/";
		},
		getCookie : function (cname) {
			var name = cname + "=";
			var ca = document.cookie.split(';');
			var i = ca.length;
			while (i --) {
				var c = ca[i];
				while (c.charAt(0)==' ') {
					c = c.substring(1);
				}
				if (c.indexOf(name) == 0) {
					return c.substring(name.length,c.length);
				}
			}
			return "";
		},
		init : function () {



			var currCookieVal = cookieManagment.getCookie('cdc_s_vi');

			if (!currCookieVal.length || currCookieVal.indexOf('[CS]v1') != -1) {
				var newCookieVal = cookieManagment.getUuid('[CS]v2') + "-" + cookieManagment.getUuid('');
				cookieManagment.setCookie("cdc_s_vi", newCookieVal, 7);
				return newCookieVal;
			}
			return currCookieVal;
		}
	};


	var cdcSessionID = cookieManagment.init();

	s3 = s_gi("cdcgovvistorid");

	var sKey, override = {
		fun: "cdcgovvistorid",
		trackingServer: "cdc.112.2o7.net"
	};

	s3.visitorID = cdcSessionID;

	for (sKey in s) {
		if (s.hasOwnProperty(sKey)) {
			if (override.hasOwnProperty(sKey)) {
				s3[sKey] = override[sKey];

			} else {

			}
		}
	}
	updateVariables(s3);


	var s_code_uvid = s3.t();
	if(s_code_uvid) {
		document.write(s_code_uvid);
	}
}




</script>
<script type="text/javascript">
if(navigator.appVersion.indexOf('MSIE')>=0) { document.write(unescape('%3C')+'\!-'+'-'); }
</script>
<noscript><a href="http://www.omniture.com"><img src="https://smtrics.cdc.gov/b/ss/cdcgov/1/H.21--NS/01/H.21--NS/0" height="1" width="1" alt="Web Analytics" /></a></noscript><!--/DO NOT REMOVE/-->
<!-- End SiteCatalyst code version: H.21. -->
<!-- Begin Template Package DigitalGov Search Support -->
<script type="text/javascript" src="../../../JScript/rd_search.js"></script>
<!-- End Template Package DigitalGov Search Support -->
</div>
<!-- xxxxxxxxxxxxxxxxxx METRICS code ends here xxxxxxxxxxxxxxxxxxxxxxxxxxx-->
<script>if (typeof page_timing !== 'undefined') { page_timing.metrics_end = Date.now(); }</script>
				


<!--[if IE]>
<script defer language="javascript" type="text/javascript">
		var cdcLeftNav = new CDC.LeftNav("nav-primary", "/niosh/pubs/all_date_desc_nopubnumbers.html", true, true);
		cdcLeftNav.render();
</script>
<![endif]-->
<!--[if ! IE]><!-->
<script language="javascript" type="text/javascript">
$().ready(function(){
		var cdcLeftNav = new CDC.LeftNav("nav-primary", "/niosh/pubs/all_date_desc_nopubnumbers.html", true, true);
		cdcLeftNav.render();
});
</script>
<!--<![endif]-->


    	



						    </body>
	</html>
